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1   Introduction 
 
Membrane G-protein coupled receptors (GPCR) and intracellular second 
messengers such as calcium, phosphoinositides, cAMP and cGMP play a central 
role in the communication between numerous cells of an organism, providing a 
fast response to rapidly changing physiological conditions in order to maintain 
homeostasis and finely regulate multiple functions inside a cell. 
Biochemical science of the 20th century made it possible to understand and 
thoroughly characterize basic principles of intracellular signalling. Despite their 
ease of use, good performance and availability, standard biochemical methods 
have only a relatively low temporal resolution, i.e. they can measure a certain 
biochemical parameter or biological function on the scale of seconds, whereas 
the most important processes of cellular signalling have emerged to occur as 
rapidly as on the millisecond scale. Moreover, standard techniques required a 
batch of cells to be destroyed in order to yield a small amount of the cytosol to 
measure the concentrations or activity of the molecules of interest. This does not 
allow to achieve a higher, subcellular spatial resolution and to study the 
behaviour of a single live cell. 
At the end of the last century novel microscopic techniques were developed, 
which combined with fluorescence have for the first time allowed to monitor 
biochemical events inside a single live cell. They gave an opportunity to study 
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intracellular processes with a high temporal (millisecond scale) and spatial 
(nanometre range) resolution and to increase our understanding of cell 
physiology. Single cell fluorescence microscopy has also made it possible to get 
new insights into the pathophysiology of different diseases and to search for 
therapeutic agents that have a distinct molecular mechanism of action at the 
level of the molecules involved in intracellular signalling.  
 
1.1   cAMP and cGMP cascades and their physiological 
significance  
 
Cyclic adenosine monophosphate (cAMP) was discovered in the early 1950s 
as an intracellular regulator of glucose metabolism, which was responsible for 
the modulation of the glycogen phosphorylation in response to noradrenalin 
stimulation1-3. Later on it was appreciated that β-adrenergic receptors couple to 
the class of G proteins called Gs (s for stimulatory), which in turn are capable of 
activating adenylyl cyclases located in the plasma membrane and producing 
cAMP from ATP4-9  (Fig. 1). The complexity of the cascade from the receptor to 
cAMP-production has at least two biological functions. First, it enables multiple 
mechanisms and modalities of regulation of the signalling through the modula-
tion of receptor activity (e.g. by receptor kinases, phosphatases and arrestins)10, 
G-protein cycle (e.g. by RGS proteins)11,12 and adenylyl cyclase (e.g. by other 
receptors through Gi-proteins, i for inhibitory)13. Secondly, there is an 
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amplification of the signal, which occurs in the cascade. One activated receptor 
can switch on several G-proteins, each of which activates an adenylyl cyclase, 
producing thousands of cAMPs per second.  This amplification results in a 
production of micromolar amounts of the second messenger in response to 
nanomolar hormone concentrations, and this leads to a high sensitivity of a cell 
towards the constantly changing physiological conditions in order to provide a 
fast and adequate response14.  
 
Fig. 1. cAMP and cGMP signalling cascades in a typical animal cell and their 
interactions. cAMP is produced by the family of G-protein-regulated adenylyl cyclases 
and elicits its effects in a cell by activating three kinds of effectors: PKA, Epac and 
cyclic nucleotide-gated channels. cGMP is a second messenger, which is 
synthesized by soluble NO-activated (sGC) or a membrane-bound (particulate) 
guanylyl cyclase (GC), located in the intracellular domain of an ANP-receptor. Three 
classes of cGMP targets are cGMP-dependent protein kinases (GK), cGMP-activated 
phosphodiesterases (PDE) and cGMP-gated channels.     
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Being an ubiquitous second messenger cAMP regulates a wide variety of 
cellular events and biological processes from metabolism and gene expression15, 
cell division16 and migration17, exocytosis18 and insulin secretion19 to immune 
defence20, memory formation21 and cardiac frequency22. How can such a small 
molecule account for hundreds of biological effects? Since its discovery in the 
1950s until the end of the last century only one single effector of cAMP, namely 
cAMP-dependent protein kinase (PKA), was supposed to convey all cAMP 
effects in different cells1,23. PKA is a complex enzyme, which in higher animals 
consists of four subunits, two regulatory and two catalytic, brought together by a 
series of intermolecular interactions23,24. In protozoa, such as Dictyostelium 
discoideum, PKA is a complex of only one regulatory and one catalytic subunit. 
The catalytic subunits are only active when they are released from the regulatory 
subunits as a result of the complex activation by cAMP (Fig. 1, Fig. 2). Each 
regulatory subunit has two binding sites, which bind cAMP with different 
affinities. Cooperative occupation of both leads through a series of 
conformational rearrangements to the release of the catalytic subunits from the 
complex23-25. Free catalytic subunits are then active and can phosphorylate a 
myriad of substrates regulating diverse intracellular functions until it becomes 
proteolytically degraded or binds again to a regulatory subunit23,26. The catalytic 
subunit can freely diffuse through the pores into the nucleus, where it activates 
CREB, which is a protein that regulates transcription of many different genes15. 
Another classical example of a PKA substrate is an L-type calcium channel, 
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which accounts for calcium influx and enhanced contractility of cardiac 
myocytes after adrenergic stimulation27,28.  
In 1998 it became evident that PKA represents not the only target of cAMP. At 
that time new avenues for cAMP research were opened up by the discovery of 
exchange protein directly activated by cAMP (Epac)29,30, which is expressed in 
the brain31, heart, liver and some further tissues32. In addition to PKA, Epac 
serves as an important intracellular effector for cAMP33. Epac is a protein 
consisting of a regulatory cAMP binding site and a catalytic domain (Fig. 2), 
which has the function of GTP-loading of a small G-protein, Rap1, and 
maintaining its active state (Fig. 1). Rap1 has several functions including the 
modulation of MAPK-kinase cascade through Raf-133,34 and cell adhesion 
through the regulation of integrin expression35,36. Another important function of 
Rap1 is the stimulation of exocytosis. It was demonstrated that Epac binds to 
Rim (Rab3-interacting molecule, Rab3 being a small G protein), which is a 
putative regulator of fusion of vesicles to the plasma membrane. Epac, through 
its interaction with Rim2, mediates in neuron-like PC12 and insulin-secreting 
cells cAMP-induced, calcium-dependent secretion that cannot be blocked by an 
inhibitor of PKA18. Epac-dependent regulation seems also to play a central role 
in insulin secretion. 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3',5'-cyclic 
monophosphate (8-pCPT-2'-O-Me-cAMP), which is a selective Epac activator, 
acts in human pancreatic beta-cells and INS-1 insulin-secreting cells to mobilize 
calcium from intracellular stores via Epac-mediated calcium-induced calcium 
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release (CICR). The cAMP-dependent increase of intracellular calcium that 
accompanies CICR is shown to be coupled to exocytosis. Interaction of cAMP 
and Epac to trigger CICR explained the blood glucose-lowering properties of an 
insulinotropic hormone (glucagon-like peptide-1), which is now under 
investigation for use in the treatment of type-2 diabetes mellitus37,38.   
The third intracellular target of cAMP that has been identified around two 
decades ago are the cyclic nucleotide-gated channels which are present in 
olfactory epithelium of the nose and in semen. The family of hyperpolarization-
activated, cyclic nucleotide-modulated (HCN) channels are crucial for a range of 
electrical signalling, including cardiac and neuronal pacemaker activity, setting 
resting membrane electrical properties and dendritic integration39. These non-
selective cation channels are activated by membrane hyperpolarization and 
modulated by the binding of cyclic nucleotides such as cAMP and cGMP (Fig. 
2)40. The cAMP-mediated enhancement of channel activity is largely responsible 
for the increase in heart rate caused by β-adrenergic agonists41. 
Computer-based analysis of the protein sequence databases has allowed to find 
some further candidates to bind cAMP and maybe responsible for some yet 
unknown functions of this second messenger42. One such candidate is 
neuropathy target esterase (NTE), which is a large transmembrane protein with a 
serine esterase activity, catalysing hydrolysis of lysophospholipids. It is 
abundantly expressed in neurons of the brain, but also in a variety of non-
neuronal tissues including intestine, placenta, testis and kidney. NTE inhibition 
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by organic phosphorus esters is responsible for the delayed neuropathy 
characterised by a paralysis of the lower limbs due to degeneration of long 
axons in the spinal cord and in peripheral nerves. The catalytic domain of NTE 
is located in the C-terminal part of the protein; the N-terminal part, which 
contains the three putative cNMP-binding domains, may serve as a regulatory 
domain42.  
In summary, three classes of functionally significant cAMP targets have been 
demonstrated so far. cAMP conveys its effect in cells by activating PKA, Epac 
and cAMP-gated channels. 
 
Fig. 2. Cartoon depiction of modular structures of cellular proteins that interact with 
cAMP and cGMP. cAMP binds to A and B domains of regulatory subunit of PKA, as 
well as to regulatory domains of Epacs and CNG/HCN channels. cGMP interacts with 
high affinity A and low affinity B domains of GK, with regulatory GAF domains of 
PDEs and also with CNBD of the channels. DEP – Dishevelled, Egl-10, Pleckstrin 
domain, responsible for membrane targeting of Epac. 
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Another ubiquitous and important second messenger is cyclic guanosine 
monophosphate (cGMP), which is produced by two kinds of guanylyl cyclases 
(Fig. 1). Membrane-bound guanylyl cyclase is represented by an intracellular 
domain of natriuretic peptide receptors (NPR)43,44. These receptors, unlike 
GPCR comprised of seven transmembrane helices, consist of 3 distinct domains: 
extracellular domain, transmembrane region and intracellular domain. The 
extracellular domain is supposed to bind peptide ligands, members of the 
natriuretic peptide family ANP (atrial), BNP (brain) or CNP (C-type) natriuretic 
peptides. These are peptide hormones (22-27 amino acids), which are produced 
by specialized secretory cells in response to elevated blood volume. For 
example, in cardiac atrium secretion of ANP is induced by hypervolemia45. The 
physiological role of ANP is to reduce blood volume by stimulating kidney 
excretion sodium and, hence, water through inhibition of aldosterone 
production, which is under the control of cAMP-stimulating adrenocorticotropic 
hormone (ACTH).  Such a negative feed-back loop of hormone regulation ends 
up in the aldosterone producing cells of the adrenal zona glomerulosa. 
Activation of ANP-receptors in these cells induces their conformational 
change46, activating through the transmembrane helix the intracellular domain of 
the receptor bearing the guanylyl cyclase, which starts to synthesize cGMP. The 
latter is a freely diffusible second messenger that activates a specific 
phosphodiesterase PDE2, which hydrolyzes cAMP and this in turn reduces 
aldosterone production47,48. There have been three types of NPR receptors 
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described, which differ in their ligand binding properties and domain 
architecture. NPR-A receptors bind ANP and BNP, NPR-B - only CNP.  NPR-C 
receptor binds all three peptides but lacks the intracellular guanylyl cyclase 
domain. Its function is to bind and degrade the peptides, reducing their 
concentrations in the blood and in tissues44.   
The second type of guanylyl cyclases is a soluble guanylyl cyclase49, which is 
located in the cytosol of almost all mammalian cells and mediates a wide range 
of important physiological functions, such as inhibition of platelet aggregation, 
relaxation of smooth muscle, vasodilatation, neuronal signal transduction, and 
immunomodulation50. This enzyme is a heterodimeric protein consisting of α- 
and β-subunits, and expression of both subunits is required for catalytic 
activity51-53. Each subunit has an N-terminal regulatory domain and a C-terminal 
catalytic domain that shares sequence homology with the corresponding 
domains in membrane-bound guanylyl and adenylyl cyclases54-56. Soluble GC is 
activated by nitric oxide (NO), a paracrine vasorelaxant initially termed EDRF, 
for endothelium derived relaxant factor57 (Fig. 1). In experiments as well as in 
clinical therapy this GC could be switch on by the so-called NO-donors, 
substances that release NO once having appeared in the cytosol of a cell, e.g. 
sodium nitroprusside (SNP) and nitroglycerine .   
cGMP is a key player in the regulation of various physiological processes, 
including smooth muscle tone58, neuronal excitability59, epithelial electrolyte 
transport60, phototransduction in the retina61-63, and cell adhesion64. The effects 
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of cGMP in cells are exerted by activation of three different effectors (Fig. 1): 
cGMP-dependent protein kinase (GK), cGMP-activated isoforms of PDE58 
and cyclic-nucleotide-gated ion channels65,66.  
GK is a well characterized protein kinase, which is activated by cGMP and 
phosphorylates numerous target proteins. In contrast to PKA, GK is a single 
chain kinase, containing regulatory and catalytic domains in one protein of 
around 700 amino acids (Fig. 2). Elevation of intracellular cGMP induces a 
binding-dependent activation of GK leading to the catalytic transfer of the 
phosphate from ATP to a serine or threonine residue on the target protein. This 
phosphorylated protein then mediates the translation of an extracellular stimulus 
into a specific biological function. Two different genes for GK have been 
identified in mammals. One gene is located on human chromosome 10 and 
codes for the Ia and Ib isoforms, which arise from alternative splicing of the N-
terminal region67. The other is located on human chromosome 4 and encodes 
GK II 68. GKI is a cytosolic 76-kDa homodimer widely expressed in mammalian 
tissues, especially in cerebellum, platelets, and smooth muscle69. The difference 
in the N-terminal domain between two GK subtypes confers different binding 
affinities for cGMP. GKIa has high and low affinity binding sites that display 
positive cooperative behaviour. GKIb has two cGMP binding sites characterized 
by lower affinity and cooperativity59,67. GKIa is mainly detected in the vascular 
system, kidney, and adrenal gland, whereas GKIb is expressed in the uterus67. 
GKII is an 86-kDa membrane-bound homodimer. It is absent from the 
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cardiovascular system, abundant in brain and intestine, and is also expressed in 
lung, kidney, and bone69-71. The amino acid sequence of GKII differs from that 
of GKI principally at the N-terminus, where unique sites direct intracellular 
localization of the enzyme. GKII contains a myristoylation site that is required 
for membrane association69. A major difference between the two GKs is that the 
cGMP binding sites in GKII have much lower affinity and cooperativity. 
Another difference is a significant divergence in their substrate selectivity59. 
Moreover, the two forms of GK are expressed in different cells, with the 
exception of chondrocytes in the growth plate in the tibia of newborn mice72. All 
known GKs are composed of N-terminal, regulatory, and catalytic domains. The 
N-terminal domain contains five regulatory sites: (1) the subunit dimerization 
site, consisting of an α-helix with a conserved leucine/isoleucine repeat; (2) 
autoinhibitory sites, involved in the inhibition of the catalytic domain in the 
absence of cGMP; (3) autophosphorylation sites, which in the presence of 
cGMP may increase the basal catalytic activity and the affinity of GKs for 
cAMP; (4) a site regulating the affinity and the cooperative behaviour of the 
cGMP binding sites; and (5) the intracellular localization site, which determines 
the interaction of the enzyme with specific subcellular structures. The regulatory 
domain contains two cyclic nucleotide binding sites termed “A” and “B” that 
allow for full activation of the enzyme after specific binding of two molecules of 
cGMP (Fig. 2). Finally, the catalytic domain, located at the C-terminus, contains 
the binding sites for Mg-ATP and the target protein59,60,69.  
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A broad range of proteins are phosphorylated by GKs. GKI is supposed to 
primarily regulate intracellular calcium in the cytosol, while GKII modulates 
fluid homeostasis at the cell membrane. Biological substrates for GKI may be 
conceptually subdivided into three main groups, “classical,” “new,” and 
“hypothetical” targets. “Classical” targets are clearly recognized as substrates, 
in vitro and/or in vivo, are phosphorylated by GKI, and have well established 
functions. This group includes: (1) the inositoltrisphosphate (IP3) receptor and 
phospholamban (cGMP-mediated phosphorylation leads to calcium 
sequestration in the endoplasmatic reticulum), which are primarily implicated in 
smooth muscle cell (SMC) relaxation73,74; (2) the vasodilator-stimulated 
phosphoprotein (VASP) and vimentin, which are involved in platelet and 
neutrophil activation, respectively75,76; (3) the G substrate, which is strongly 
expressed in cerebellar Purkinje cells where it acts as a phosphatase inhibitor77; 
and (4) the thromboxane A2 receptor, whose activation was found to be 
inhibited by GK-mediated phosphorylation in platelets78. “New” target proteins 
are GKI substrates that either have been described recently or have conflicting 
evidence regarding their phosphorylation by GKI. This group includes: (1) the 
L-type calcium channel and the calcium-activated K1 channel which, upon 
phosphorylation, contribute to the regulation of vascular smooth muscle tone 
and cardiac contractility79,80; (2) the calcium-dependent cytosolic phospholipase 
A2, implicated in intestinal smooth muscle relaxation81; (3) a tyrosine 
hydroxylase whose activity in intact bovine chromaffin cells was observed to 
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increase after GKI-mediated phosphorylation82; and (4) the myosin-binding 
subunit of myosin light chain phosphatase, which mediates SMC relaxation and 
vasodilation83. Most, if not all, of these substrates are phosphorylated by the 
GKIa. “Hypothetical” target proteins have been suggested, but not 
demonstrated, to be phosphorylated by GKIb. This group contains putative 
substrates predicted on the basis of experimental demonstrations of cGMP/GKI 
mediated processes. For example, cytoskeletal and contractile proteins (i.e., 
myosin light chain, calponin, desmin, connexins) are thought to be GKIb target 
molecules in the regulation of vascular remodelling and neoangiogenesis64,84. 
Similarly, synaptic vesicle proteins (i.e., rabphilin-3A) may be phosphorylated 
by GKI and mediate synaptic plasticity and neurotransmission85-87. The 
cGMP/GKI pathway has been implicated in the control of gene expression of 
various promoter response elements (i.e., serum response element, AP-1 binding 
site, and CREB)88,89. In contrast to GKI, the only recognized classical substrate 
that is phosphorylated by GKII is the cystic fibrosis transmembrane conductance 
regulator in intestinal mucosal cells90. Localization of GKII in the apical 
membranes of the enterocytes of the small intestine permits it to phosphorylate 
this protein in response to cGMP formation. The phosphorylation of 
transmembrane conductance regulator induces an electrogenic chloride current 
and subsequent water secretion in the intestine. Co-localization and co-
regulation of the expression of GKII and a chloride channel in the inner medulla 
of rat kidney suggest that a similar mechanism may regulate renal function91,92. 
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GKII may also control the renin system and endochondral ossification and 
growth of bone72,93. However, the target molecules in these latter processes are 
unknown. 
The second important class of cGMP effectors are phosphodiesterases (PDEs). 
This is a class of enzymes consisting of 11 families including multiple isoforms 
hydrolysing cyclic nucleotides94,95. Each member contains a conserved catalytic 
domain of around 270 amino acids located on the C-terminus (Fig. 2). This 
domain cleaves the phosphodiester bond, hydrolyzing the 3’, 5’-cyclic 
nucleotide to its corresponding nucleotide, 5’- monophosphate. PDE families 1, 
2, 3, 10, and 11 hydrolyze both cGMP and cAMP; PDE families 4, 7, and 8 
preferentially cleave cAMP; and PDE families 5, 6, and 9 specifically hydrolyze 
cGMP. The activity of PDEs is crucial for cellular signalling because 
metabolism of cyclic nucleotides modulates their intracellular concentrations 
and affects subsequent cellular and behavioural responses. PDEs regulate for 
example cardiac functions, adrenal steroidogenesis, the male erectile response, 
and phototransduction58. Specific PDE targeting sites may localize the enzyme 
in close proximity to selected proteins, thereby modulating cyclic nucleotide 
levels in specific compartments. 
Cyclic GMP regulates PDEs through three different mechanisms: (1) increasing 
activity through mass action (PDE5, 6, and 9), (2) altering the rate of hydrolysis 
of cAMP through competition at the catalytic site (PDE1, 2, and 3), and (3) 
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regulating enzymatic activity through direct binding to specific allosteric sites 
(PDE2, 5, 6, 10, and 11)96.  
The cGMP binding domain in PDE2, 5, 6, and 10 contains two in-tandem 
homologous sites of about 110 amino acids located at the N terminus (Fig. 2, 
regulatory GAF-domains, from cGMP-regulated phosphodiesterases, bacterial 
Adenylyl cyclases, and transcription activator FlhA, where such domains were 
identified). They contain an amino acid sequence different from that of cyclic 
nucleotide-dependent kinases and HCN channels, representing a separate class 
of cGMP-regulated proteins96. PDE10 catalyzes the hydrolysis of both cyclic 
nucleotides, but its physiological function is still unclear. PDE2 is widely 
distributed, exists as homodimers and catalyzes the hydrolysis of cGMP and 
cAMP. Cyclic GMP binds to allosteric sites, stimulates PDE2 activity, and 
increases cGMP hydrolysis, forming a negative-feedback mechanism regulating 
intracellular cGMP. Similarly, cGMP enhances the PDE2-mediated degradation 
of cAMP, thus cross-regulating its intracellular concentration97,98. PDE5 is a 
homodimer which specifically degrades cGMP. Direct binding of cGMP to 
allosteric sites promotes phosphorylation of PDE5 by either GK or PKA, 
thereby indirectly stimulating enzyme activity. It has been suggested that 
binding of cGMP to the allosteric sites directly activates PDE5, but this effect 
has not been demonstrated in vivo 99. Finally, PDE6 in rod (PDE6A and B) and 
cone (PDE6C) photoreceptors is comprised of two large catalytically active 
subunits associated with various smaller inhibitory and a regulatory subunit. It is 
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believed that cGMP binding to allosteric sites of PDE6 regulates the interaction 
between catalytic subunits, inhibitory subunits, and transducin, an important step 
in phototransduction61. 
cAMP and cGMP represent two different signalling cascades. However, they 
interact at different levels in order to orchestrate multiple biochemical events, 
which occur in cells at the same time. One possible modality of the interaction is 
on the level of target proteins that are, for instance, phosphorylated by both PKA 
and GK. One can give many examples of those proteins such as VASP, 
phospholamban, L-type calcium channel, IP3 receptor, some GPCR (references 
cited above). GK and PKA inhibit IP3-dependent release of calcium and induce 
relaxation in dispersed rabbit and guinea pig gastric muscle cells81. Similarly, 
isoproterenol or SNP induce the phosphorylation of cytosolic calcium-dependent 
phospholipase A2 by activating PKA or GK, respectively, in SMCs from the 
longitudinal muscle layer of rabbit intestine81. The same effect is achieved by 
simultaneous stimulation of both kinases by VIP and isoproterenol, contributing 
to the relaxation response of these cells. In vertebrates, cGMP and cAMP relax 
vascular smooth muscle, inhibit platelet activation, and regulate chloride and 
water secretion in the intestine. 
Another level of cAMP/cGMP interaction is represented by PDEs. They are 
located at an intersection of cAMP and cGMP cascades. At their level cGMP is 
capable of directly regulating cAMP concentrations in a cell (Fig. 1). Several 
PDEs, e.g. PDE2 are activated by cGMP in order to reduce the intracellular 
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concentrations of cAMP and cGMP. This mechanism plays a key role in 
regulation of aldosterone secretion (see above) and is an example of antagonistic 
action of cAMP and cGMP. On the other hand, cGMP-inhibited PDE3 is 
involved in cAMP-signalling in cardiac myocytes100 or regulates electrogenic 
chloride secretion in the small and large intestine by cGMP-dependent increases 
in intracellular cAMP, and activation of PKA101. The reverse situation, i.r. a 
direct effect of the cAMP cascade on the hydrolysis of cGMP, has not been 
observed. This suggests that the cAMP-system influences the cGMP-cascade 
primarily on the level of common target proteins and their corresponding 
effectors. cAMP-specific but not cGMP-specific isoforms such as PDE4 can be 
activated by PKA phosphorylation and hydrolyze exclusively cAMP102. Two 
signalling systems therefore exist in cells, which are subject to multiple 
interactions that have not yet been fully elucidated. In the present work this issue 
was addressed by the development and use of fluorescent biosensors. 
 
1.2.   Biosensors, GFP-technology, FRET 
 
In recent decades has become possible to visualize biochemical events in single 
live cell by fluorescence microscopy techniques. These techniques are based on 
using special reporter proteins, which change their physicochemical properties 
(e.g. fluorescence spectrum) in response to particular intracellular molecules 
(ions, small second messengers such as cAMP or cGMP, various proteins or 
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even DNA). A strong contribution to the development of bioimaging techniques 
has come from the molecular cloning and subsequent engineering of the green 
fluorescent protein (GFP) from the bioluminescent jellyfish Aequorea 
victoria103. GFP is a middle size (~ 20 kDa, containing ~ 240 amino acids) 
protein with a β-barrel structure, bearing an internal chromophore group 
consisting of several interacting amino acids (Fig. 3A). GFP has several 
qualities that make it ideal for in vivo imaging. First, GFP can be expressed in a 
variety of cells, where it becomes spontaneously fluorescent without the need 
for any cofactors. Second, because it is a protein, GFP can be tagged with many 
signalling peptides or fused to other proteins targeted to specific organelles, such 
as the mitochondria, the nucleus, or the endoplasmic reticulum. Finally, 
mutagenesis of GFP has generated many mutants with varying spectral 
properties, thus allowing imaging of several different fluorescent proteins 
simultaneously104-107.  
GFP has been successfully used for several years as a marker for studying gene 
expression as well as protein folding, trafficking, and localization. Recently, 
however, more sophisticated applications have been developed by using several  
GFP-mutants to generate biosensors capable of monitoring complex processes, 
such as intracellular second messenger dynamics, enzyme activation, and 
protein-protein interactions105,108-110. 
Development of GFP-based biosensors became possible when various GFP-
mutants were cloned. They exhibited - compared to GFP - changed fluorescent 
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spectrum properties, most importantly shifted excitation and emission spectra. 
Combining two fluorescent GFP-mutants with appropriate spectra makes it 
possible to monitor intra- or intermolecular distances between them in live cells 
based on fluorescence resonance energy transfer (FRET).  
FRET is a quantum mechanical phenomenon that occurs between a fluorescence 
donor and a fluorescence acceptor that are in molecular proximity of each other 
if the emission spectrum of the donor overlaps the excitation spectrum of the 
acceptor. Examples for this are enhanced cyan fluorescent protein (CFP) and 
enhanced yellow fluorescent protein (YFP) (Fig. 3B). Under these conditions, 
energy is transferred non-radiatively from the donor to the acceptor with an 
efficiency E defined by the equation (Fig. 2A), where r is the distance between 
two fluorophores and R0 (Förster distance) is the distance at which 50 % energy 
transfer takes place (typically 20-60 Å). The latter is dependent on the extent of 
spectral overlap, the quantum yield of the donor and the relative orientation of 
the donor and acceptor105. In FRET experiments, the donor is excited by incident 
light, and, if an acceptor is in close proximity, the excited state energy from the 
donor can be transferred. This leads to a reduction in the donor’s fluorescence 
intensity and excited lifetime and an increase in the acceptor’s emission 
intensity. According to the Förster equation, a doubling of the distance between 
the two fluorophores, for example from R0 to 2R0, may decrease the efficiency 
of transfer from 50 % to 1.5 %. Therefore, FRET provides a very sensitive 
measure of intermolecular distances and conformational changes. 
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The generation of GFP mutants with distinct excitation and emission spectra, as 
well as the molecular cloning of new fluorescent proteins from Fungia concinna 
(orange fluorescent protein)111 and coelenterate marine organisms112 has 
provided several fluorophores that can serve as FRET donor/acceptor pairs. 
When selecting fluorescent proteins to use as workable FRET pairs, three 
spectroscopic properties of the donor and acceptor should be considered. First, 
there needs to be sufficient separation in excitation spectra to achieve a selective 
stimulation of the donor. Second, there needs to be an overlap between the 
emission spectrum of the donor and the excitation spectrum of the acceptor to 
obtain efficient energy transfer. Third, reasonable separation in emission spectra 
between donor and acceptor fluorophores is required to allow the fluorescence 
of each fluorophore to be measured independently113. To date, the mostly and 
successfully used donor-acceptor pair is the CFP–YFP combination (Fig. 3B).  
A lot of effort is being placed on the search for more red-shifted fluorescent 
proteins (RFPs) to be used as FRET acceptors in combination with a GFP donor. 
RFPs would provide greater tissue penetration and minimize tissue 
autofluorescence background; however, additional improvement of the existing 
proteins will be necessary for their useful application in FRET experiments. The 
major limitation of the original dsRed protein is that it forms tetramers and can 
therefore tetramerize a cellular protein to which it is fused, leading to large 
aggregation of the fusions. By a combination of site-directed and random 
mutagenesis, a monomeric variant of this RFP has been generated (mRFP1) in  
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Fig. 3. General principles of GFP-based fluorescent biosensors. A. Crystal structure 
of GFP, which is composed of numerous β-sheets forming the so-called β-barrel. The 
chromophore is a group of amino acids interacting in the core of the barrel (in grey). 
On the right – a general equation to calculate Förster resonance energy transfer 
efficiency (explained in text). B. Normalized excitation (left) and emission (right) 
spectra of CFP (cyan) and YFP (green) fluorescent proteins commonly used as a 
FRET-pair. Extensive overlap of the CFP emission and YFP excitation spectra is a 
basis for FRET. C.  Schematic representation of a bimolecular biosensor, consisting 
of two proteins X and Y fused to YFP and CFP, respectively. Intermolecular FRET 
appears when the proteins are interacting. D. Principle of a monomolecular 
biosensor, where a protein sequence (here containing two different domains X and 
Y) is sandwiched between CFP and YFP. Interaction between the domains leads to a 
conformational change monitored by a change in intramolecular FRET.   
 
which most of the problems of dsRed have been overcome. However, mRFP-1 
performance as a FRET acceptor remained seriously hampered by the very long 
tail of its excitation spectrum on the short wavelength side, leading to direct 
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excitation of the acceptor when exciting the donor113. For this reason, very 
recently a series of new red-shifted fluorescent proteins was developed by 
subjecting mRFP1 to many rounds of directed evolution. The properties of the 
resulting variants include several new colours (banana, strawberry, tomato, 
honeydew, and cherry) and improvements of extinction coefficients, quantum 
yields and photostability106.  
GFP-based FRET biosensors follow two basic designs. One option is to use 
bimolecular probes, in which the fluorophores are fused to two independent 
domains or proteins whose interaction depends on ligand binding or a 
conformational change in the separate domains. In  this  case  the intermolecular  
FRET is measured, which increases when two proteins interact or decreases 
upon protein dissociation (Fig. 3C). Monomolecular probes are based on 
intramolecular FRET between CFP and YFP fused to a protein sequence 
interacting with a molecule of interest. Binding of the specific ligand to this 
sequence leads to a conformational change, which is monitored by FRET (Fig. 
3D).  In general, monomolecular sensors may be preferable because a single, 
monomolecular probe is less likely to interact with bystanding partners. Such 
interaction may interfere with endogenous reactions and thus affect cell 
physiology and reduce the probe sensitivity. Monomolecular constructs have an 
additional advantage of containing equimolar amounts of the donor and acceptor 
fluorophores, therefore allowing maximal exploitation of the dynamic range of 
FRET changes and facilitating quantification.  
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Up to date, there have been tens of biosensors developed covering multiple 
intracellular processes109. Just a few examples of monomolecular sensors are: 
cameleons to monitor intracellular calcium114,115, sensors for phospholipase C 
activation116 and phosphoinositides117, reporters of activity of different protein 
kinases (where a target sequence for a particular kinase is sandwiched between 
GFP variants)118-120. Bimolecular biosensors are tools to monitor interactions 
between proteins, for example between the subunits of trimetric G-proteins121,122 
or between regulatory of catalytic subunit of the PKA123,124. They will be 
discussed in detail in the following two parts of the introduction (see 1.3 and 
1.4). 
Several FRET microscopy techniques are available for measuring biosensors 
in live cells. Wide-field microscopy is the simplest and most widely used 
technique110. FRET is typically measured as the ratio of acceptor emission to 
donor emission on excitation of the donor, giving a value that is proportional to 
the degree of physical association between the two fluorophores. One of the 
major drawbacks of wide-field microscopy is the generation of an out-of-focus 
signal. This can be a serious problem, especially when relatively thick samples 
are inspected and when the goal of the experiment is to study molecular events 
that take place in restricted volumes within the cell. Laser scanning confocal 
microscopy125 solves this problem and, by collecting serial optical sections from 
thick specimens, allows resolving FRET signals in 3 dimensions. A major 
limitation of confocal microscopy is the availability of standard laser lines of 
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defined wavelength that normally do not allow one to resolve FRET. A recent 
technological advance, however, has introduced multiphoton confocal 
microscopy that, by using a tuneable laser in the 700- to 1000-nm range, allows 
the excitation of a wide variety of fluorophores with higher axial resolution, 
greater sample penetration, limited photobleaching of the fluorophores, and 
reduced damage of the sample125.  
The intensity-based FRET techniques described above suffer from 
contamination of the FRET images with unwanted bleedthrough components 
because of the incomplete separation of the donor and acceptor excitation and 
emission spectra. When using CFP/YFP, for example, excitation of CFP is 
associated with partial direct excitation of YFP, which therefore will emit 
independently of FRET. Even more important is the bleedthrough of CFP 
emission in the YFP channel, which can contribute up to 80 % of the FRET 
image. The degree of crosstalk between fluorophores must be assessed for each 
individual imaging system, and careful choice of filter sets can minimize 
bleedthrough. Moreover, the degree of crosstalk should be carefully measured 
and be accounted for in the offline image processing phase126, which should 
include corrections for bleedthrough and direct YFP excitation. Recently, a new 
algorithm has been developed that removes both the donor and acceptor 
bleedthrough signals and corrects the variation in fluorophore expression level, 
generating a true FRET signal125. 
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Fluorophore crosstalk is a particularly serious problem when looking at steady-
state, intermolecular FRET. In this situation, the intracellular molar ratio 
between donor and acceptor is difficult to control, and different concentrations 
of the two fluorophores may be misinterpreted as FRET. Such a problem is 
completely overcome if an intermolecular FRET sensor and the experimental set 
up allow monitoring of dynamic FRET. In this case, it is possible to establish 
whether a change in donor to acceptor fluorescence is a true change in FRET by 
monitoring donor and acceptor fluorescence intensity over time. A true FRET 
change corresponds to a symmetric change of donor and acceptor fluorescence 
intensity (e.g. in case of an increase in FRET – simultaneous increase in the 
donor and decrease in acceptor fluorescence). Another approach for imaging 
steady-state FRET consists in collecting the donor emission before and after 
photobleaching of the acceptor. If FRET is present, elimination of the acceptor 
by photodestruction releases the energy transferred from donor to acceptor with 
consequent brighter emission from the donor. This method is very simple and 
can be used in any laboratory equipped with a simple fluorescence microscope. 
However, the correct interpretation of the results obtained is not always 
straightforward, especially if FRET efficiency is low127,128. An alternative 
method for measuring FRET is via donor photobleaching129. This technique 
exploits the fact that photobleaching is proportional to the excited-state lifetime 
of the fluorophore. Because FRET reduces the lifetime of the donor’s excited 
state, its photobleaching rate decreases proportionally. 
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Apart from the intensity-based methods described above, more sophisticated 
technologies for measuring FRET are also available. Fluorescence lifetime 
imaging microscopy takes advantage of the fact that FRET results in a 
shortening of the donor’s lifetime; by subtracting the fluorescence lifetime of the 
donor alone from the lifetime of the donor in the presence of the acceptor, the 
efficiency of FRET can be measured130,131. Another technique is fluorescence 
correlation spectroscopy, in which spontaneous fluorescence intensity 
fluctuations are measured in a microscopic volume and energy transfer 
efficiency of freely diffusing single molecules can be accurately measured132,133. 
 
1.3.   Biosensors for receptors, G-proteins and second messengers  
 
In this section, the most important biosensors will be characterized, which are 
used to monitor the activity of different players in a typical GPCR-pathway (Fig. 
1). These include the probes designed for monitoring GPCR activation, G-
protein activation and cAMP production in live cells.  
Binding of specific ligands to a family of seven-transmembrane receptors  is 
supposed to induce an intracellular response through activation of G-proteins 
and downstream enzymes such as adenylyl cyclase and phospholipase, which 
produce second messengers (cAMP, phosphoinositides and calcium) triggering 
numerous biochemical events in a cell. This multistep mechanism provides 
amplification of the signal and different modalities of regulation (see 1.1). Using 
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numerous fluorescent biosensors it became possible to monitor such signaling 
events in a single live cell. 
GPCR activation could be monitored as a change of FRET using a 
monomolecular sensor consisting of the receptor fused to two fluorophores: CFP 
as a donor on the C-terminus of the receptor and YFP or Flash as an acceptor in 
the 3rd intracellular loop of the receptor (Fig. 4A)134,135.  A ligand-induced 
conformational change in the receptor leads to an increase of distance between 
the 3rd intracellular loop and the C-terminus of the receptor, which could be 
easily monitored in live cells as a decrease in intramolecular FRET of the 
biosensor. Initially such chimeric receptors were created using the CFP-YFP 
FRET pair to watch activation of α2A-adrenergic and parathyroid hormone 
receptors134. Later on YFP was replaced by the smaller organic Flash 
fluorophore, which has a small size and improves the signaling properties of the 
chimeric receptor (in terms of coupling to G-proteins), which physiologically 
becomes now undistinguishable from a normal untagged receptor135. Flash is a 
fluorescein derivative containing two AsH groups, which shows no fluorescence 
until it is covalently bound to a specific helical amino acid motif (CCPGCC), 
which can be introduced into different proteins for their specific labeling136,137. 
Flash bound to the 3rd intracellular loop of the receptor (such sensors have been 
reported for adenosine A2A- and adrenergic α2A-receptors) serves as a 
fluorescence acceptor of CFP. Receptor conformational switch upon activation 
leads to a decrease of FRET between CFP and Flash occurring within a few tens 
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 Fig. 4. Examples of fluorescent biosensors for GPCR and G-proteins. A. A 
monomolecular sensor for monitoring of the receptor activation switch. Adrenergic 
α2A-receptor is fused to CFP on the C-terminus and has an inserted six amino acid 
sequence to bind the acceptor fluorophore Flash in the 3rd intracellular loop. Due to a 
conformational change in the receptor upon binding of norepinephrine (NE) a rapid 
decrease in intramolecular FRET was monitored as a measure of receptor activation. 
Live cell experiment. Fluorescence intensities in single Flash and YFP channels and 
their ratio are presented. B. System for monitoring Gi-protein activation consists of an 
αi2 subunit tagged with YFP, γ2-subunit fused to CFP and unlabeled β1-subunit122. A 
decrease in intermolecular FRET is observed in cells stably expressing α2A-
adrenergic receptor upon activation with NE. 
 
of milliseconds (Fig. 4A). Withdrawal of the ligand returns the receptor in the 
initial conformation (Fig. 4A). A pharmacological application of this biosensor 
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is to study and screen compounds acting on the level of GPCRs (these represent 
around one third of all currently used drugs), because the sensor can effectively 
differentiate between full agonists, antagonists/reverse agonists and inverse 
agonists of the receptors134.    
Another group of biosensors was designed to monitor G-protein activation. 
This field was pioneered by Janetopoulos and colleagues who analyzed receptor-
induced G-protein activation in live Dictyostelium discoideum cells by 
monitoring FRET between α- and β-subunits of G-protein fused to CFP and 
YFP. The G-protein heterotrimer rapidly dissociated and reassociated upon 
addition and removal of chemoattractant121. Later on similar sensors were 
developed for mammalian Gi proteins and it was demonstrated that those 
subunits do not dissociate upon activation, but rather undergo a conformational 
rearrangement. When fusing YFP to αi2 and CFP to the C-terminus of the γ2 
subunit, a predicable decrease in FRET was observed (Fig. 4B). However, if the 
CFP was placed at the N-terminus of the γ2- or β1-subunit, an increase in FRET 
was observed indicating that the Gi subunits stay together and that a 
conformational rearrangement takes place within the complex122. The described 
biosensor allows monitoring G-proteins activation in single live cells, which in 
the case of Gi occurs within ~ 1 second (Fig. 4B)122. 
The next level of signalling that could be analyzed using fluorescent biosensors 
is the production and intracellular distribution of second messengers. One 
very important second messenger is calcium which is accumulated in cells as a 
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result of L-type calcium channel activation, CICR or released from intracellular 
stores (see 1.1). The classical way to image calcium in live cells is to use cell-
permeable fluorescent dyes such as Fluo, BAPTA or Fura138. Over the last 8 
years, several protein-based probes have been developed that are based on FRET 
between CFP and YFP fused to a protein sequence containing a calcium-binding 
protein, calmodulin. Calcium induces a conformational change in the sensor, 
which is monitored as a change of intramolecular FRET114,115,138,139. The protein-
based sensors due to the possibility to target them to distinct intracellular 
locations allowed for the first time monitoring of calcium in living animals and 
at the subcellular level, e.g. visualizing of calcium uptake into the mitochondria 
during skeletal muscle contraction140.  
Another second messenger, which regulates CICR through its receptors on the 
endoplasmatic reticulum, is IP3. This second messenger is produced by 
phospholipase C after the stimulation of Gq-protein coupled receptors. To 
visualize IP3 in live cells a biosensor was developed based on a sequence of the 
IP3-receptor sandwiched between YFP and CFP141. Another approach to monitor 
the signal transduction through the Gq-pathway is to image the activation of 
phospholipase C by means of FRET-biosensor, which consists of the PH-
domain of this enzyme fused to CFP or YFP. The activation results in a 
translocation of the fluorescent probes to the plasma membrane with an increase 
in FRET116.  
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1.4   FRET-sensors for cAMP and cGMP based on protein kinases   
and their disadvantages 
 
Measurements of cAMP and cGMP using FRET-based biosensors first became 
possible by monitoring the activation of the main intracellular targets for these 
second messengers, namely PKA and GK, which were initially thought to be 
exclusive effectors of cyclic nucleotides. 
The first attempts to visualized cAMP in live cells based on the dissociation of 
PKA go back to the early 1990-es, when the first biosensor for cAMP was 
created. The sensor consisted of a PKA in which the catalytic (C) and regulatory 
(R) subunits were each labelled with a different fluorescent dye such as 
fluorescein or rhodamine capable of FRET in the holoenzyme complex R2C2. 
When cAMP molecules bind to the regulatory subunits, the catalytic subunits 
dissociate, thereby eliminating energy transfer. The change in the fluorescence 
emission spectrum allowed cAMP concentrations and the activation of the 
kinase to be nondestructively visualized in single living cells microinjected with 
the labelled holoenzyme142. At that time, when GFP-technology was not yet 
established, it was the only way to label proteins with organic fluorophores to 
construct a biosensor. This first cAMP biosensor was successfully used to image 
cAMP in sensory neurons143 and neural circuits144, but the sensor was not widely 
applied due to several limitations such as the need to use purified proteins, 
microinjections and instability of the probes. Later on, when the GFP-technolo- 
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Fig. 5. Schematic representation and principles of kinase-based sensors for cAMP 
and cGMP. A. cAMP is measured as the dissociation of the PKA holoenzyme. In the 
absence of cAMP, PKA-sensor is a complex of two regulatory (R) and two catalytic 
(C) subunits fused to CFP and YFP, respectively, and high FRET is observed. After 
cAMP binding to the two sites in each regulatory subunit, catalytic subunits are 
released from the complex, which results in the loss of FRET. B. cGMP-biosensor 
based on GK (cygnet) consists of a mutant N-terminally truncated by 70 amino acids 
of the kinase still bearing regulatory (R) and catalytic (C, or mutated catalytically 
dead) domains sandwiched between CFP and YFP. Binding of cGMP to the two 
regulatory sites induces a conformational change, which is monitored as a decrease 
in FRET.   
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gy has been developed, the organic fluorophores on the PKA were replaced first 
by blue fluorescent protein (BFP) and GFP123, and subsequently with a more 
convenient FRET-pair, CFP-YFP124 (Fig. 5A). Despite being now genetically 
encoded  due to using GFP-mutants (i.e. the sensor could be expressed in live 
cells by transfecting them with two DNA constructs encoding for R-CFP and C-
YFP subunits), the sensor had several important disadvantages limiting its 
application for measuring cAMP: 
 
1. The PKA-sensor is comprised of two large proteins (R-CFP and C-YFP) 
that have to be equally expressed in cells to form a functional tetramer.  
2. Excess of catalytic subunit expression leads to detrimental consequences 
for a cell. When overexpressed alone C-subunit leads to cell death26.   
3. cAMP binding to 4 different binding sites of different affinities is a 
multistep cooperative process occurring through a series of 
conformational changes before C-subunits are released (see 1.5 for 
details)23-25. The FRET-signal reported by the sensor reflects the apparent 
complex dissociation, rather than acute changes in cAMP concentrations. 
4. Once being activated the sensor due to its C subunit exhibits catalytic 
activity, which leads to activation of PDE4 (an enzyme hydrolyzing 
cAMP); this makes, therefore, accurate cAMP measurements impossible 
(Fig. 1) 102. 
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5. The PKA-sensor could itself be anchored to distinct subcellular sites 
through interaction with A-kinase anchoring proteins (AKAPs, Fig. 1), so 
that the sensor is not equally distributed in the cytosol and might be 
directly affected by AKAPs or its interacting partners124,145. 
 
These limitations greatly hamper and complicate correct cAMP measurements 
by this PKA-sensor or their correct interpretation. 
 
A FRET approach to measure changes in intracellular cGMP has been 
developed using GKI as a backbone for a monomolecular sensor146,147. This 
protein changes its overall conformation upon cGMP binding to the two sites on 
the GK regulatory domain, which results in a decrease in FRET between CFP 
and YFP (Fig. 5B). Compared to the PKA-sensor for cAMP, this cGMP 
indicator is large but a single-chain protein, where the N-terminal anchoring, 
dimerization and autophosphorylation sites are deleted and the catalytic activity 
is switched off by a point mutation. However, the sensor still contains two 
binding sites with a complicated mechanism of activation. The major drawback 
of cygnets is a poor temporal performance in terms of physiological cGMP 
signaling. Although the sensor has a relatively high affinity for cGMP (~ 1 µM) 
it reports cGMP in live cells with an enormous delay of 50-150 seconds after the 
application of a natriuretic peptide or of a NO-donor146. Only very high (1 mM) 
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concentrations of SNP were once demonstrated to induce a rapid response148. 
This has prevented the sensor from being further applied in cGMP research. 
The aim of the present study was to develop novel biosensors for cAMP and 
cGMP which would overcome the disadvantages of the kinase-based probes and 
would contain a single cyclic nucleotide binding domain (CNBD).  
 
1.5.  Structure of cyclic nucleotide binding domains.    
Conformational change as a mechanism of activation 
 
To date there have been numerous cAMP-binding domains characterized and 
crystallized in absence or presence of cAMP. For cGMP only one regulatory 
binding domain of PDE2 has been described and crystallized in presence of the 
ligand98, whereas structures of GKs and cGMP-channels are still unresolved, 
making reliable predictions on the mechanism of the ligand induced activation 
difficult. However, using small angle X-ray scattering technique a cGMP-
dependent conformational change in the GK has been described149, which has 
also been proven by creating monomolecular FRET-based cGMP sensors using 
GK as a backbone146,147. The structure of the CNBD of PDE2 revealed a high 
degree of similarities with cAMP-binding domains, suggesting that they might 
exhibit similar mechanisms of activation, namely a cyclic-nucleotide induced 
conformational change98,150,151.  
In case of Epac the change in conformation leads to the release of the allosteric 
inhibition of the catalytic domain, which becomes active after binding of cAMP 
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in the regulatory part of the protein33. In the PKA, binding of cAMP to the high-
affinity site B induces a conformational change, giving cAMP access also to the 
A-site, which upon cAMP binding changes its conformation, leading to the 
release of the catalytic subunit24,25. In the HCN2-channel, the cAMP-induced 
conformational change is supposed to regulate the orientations of 
transmembrane domains, thereby changing the gating properties of the 
channel22. The first structural evidence for a conformational change in CNBD 
was provided by a crystal structure of Epac2, which was the first apo-structure 
of a CNBD (i.e. without cAMP)152. Comparing this structure to the known ones 
of PKA binding domains the authors took note of the different orientation of the 
helix α6:B (hinge) and proposed a conformational change as a mechanism of 
ligand-induced activation (Fig. 6A). 
Another more direct evidence for a conformational change in the B-site of the 
PKA came more recently when the cAMP-bound and ligand-free structures were 
presented for the same CNBD, the regulatory I subunit of the PKA. A major 
conformational rearrangement was observed that involved mainly the movement 
of the C-terminal hinge helix153. The next more complicated structure was 
provided for the A-domain of the same PKA in the complex with either catalytic 
subunit or cAMP (Fig. 6B). This has, for the first time, demonstrated the 
interplay between cAMP and catalytic subunit at the molecular level and 
revealed the mechanism how the cAMP-induced structural rearrangement leads 
to the release of the catalytic subunit24.  
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Fig. 6. cAMP-induced conformational change in CNBDs of Epac and PKA.  A. Crystal 
structures of the cAMP-bound B cAMP-binding domain of PKA regulatory II subunit 
(left)25 compared to a cAMP-free structure of the B-domain of Epac2152. The 
movement of the helix α6:B is proposed (black arrow) as a mechanism of activation. 
The phosphate binding cassette (PBC) is in blue. B. Mechanisms of the interplay 
between cAMP and the catalytic subunit on the A binding domain of the regulatory I 
subunit of the PKA. cAMP binding induces the release of the catalytic subunit (not 
shown) and a conformational rearrangement, characterized by a major movement of 
the C-helix (analogous to the hinge in Epac2) shown in blue. The PBC is colored  in 
red24. 
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The last two studies have thoroughly characterized the cooperative mechanism 
of PKA complex activation by cAMP, which occurs through a series of binding 
events and conformational changes: 
 
1. cAMP is first bound to the B-domain where a conformational change is 
induced (movement of the hinge helix) . 
2. The conformational change in the B-domain provides access of the ligand 
to the A-domain. 
3. cAMP binds to the A-domain where it induces a conformational change 
(movement of the C-helix). 
4. The catalytic subunit is released and becomes active to phosphorylate its 
substrates. 
 
In summary, analysis of crystal structures of different CNBDs demonstrated that 
a cyclic nucleotide-induced conformational change seems to be a ubiquitous 
mechanism for the activation of these domains and corresponding proteins: 
kinases, Epacs, channels and PDEs. In the present study, advantage was taken of 
this conformational change at the level of a single CNBD in order to create 
novel highly sensitive monomolecular biosensors to measure cAMP and cGMP 
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1.6.   Aims of the work 
 
The present study had the following goals: 
1. Development of novel biosensors for cAMP and cGMP based on single 
CNBDs for measurements. 
2. Analysis of the temporal and spatial aspects of cyclic nucleotide 
signaling. 
3. Real-time characterization of the activity of the enzymes hydrolyzing 
cyclic nucleotide (PDEs). 
4. Development of physiologically and clinically relevant systems for 
analysis of cyclic nucleotide signaling. 
5.  Characterization of the cAMP-induced conformational change in 
different binding domains using a series of cAMP analogues. 
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2   Methods and Materials 
 
2.1   Methods 
 
For generation of cAMP and cGMP biosensors, many common well established 
techniques were applied. They are described in enough details elsewhere to 
reproduce the experiments presented in the study. Characterization of 
fluorescent indicators was performed in vitro and in different live cells.   
 
2.1.1   Molecular biology techniques 
 
To produce a functional biosensor for cAMP or cGMP, DNA sequences 
encoding for CNBDs were fused with those of CFP and YFP to produce a 
chimeric fusion protein, which is supposed to exhibit a cAMP or cGMP-
dependent conformational change. The DNA constructs encoding for cAMP-
sensing proteins were generated by polymerase chain reaction (PCR) using 
human Epac1 (Acc.No. AF103905), murine Epac2 (AF115480) or murine PKA 
regulatory IIβ subunit (M12492) cDNA as a template. cGMP sensors were 
based on human GKI (NM_006258), murine PDE2A (XM_133606) and human 
PDE5A (NM_001083). Generally, the sequence of a CNBD was amplified using 
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primers encoding for EcoRI and XbaI restriction sites on N- and C-termini, 
respectively. GFP variants were amplified with standard primers from pEYFP- 
and pECFP plasmids and attached to CNBDs via EcoRI (YFP) and XbaI (CFP) 
restriction sites to produce genetic constructs encoding for fusion proteins 
schematically depicted in Figs 7A, 10, 26A, 27A. 
First, PCR was performed to amplify the respective DNA fragments. The 
standard PCR mix contained: Water (in all experiments ultrapure water was 
used from NANOpure system, Barnstead) ad 100 µl, 10x Pfu polymerase buffer 
10 µl, 10 mM desoxyribonucleotide triphosphates mix 2 µl, 20 µM forward 
primer, 20 µM reverse primer, Pfu polymerase 1 µl. The PCR program was run 
on Gene Amp2450 (Perkin Elmer): 94°C – 5 min, 20x (94°C – 30 s, 55°C – 30 
s, 72°C – t), 72°C – 7 min, 20°C - ∞. t was calculated depending on the length 
of the fragment amplified, 1000 base pairs per 120 s. The primers were designed 
to contain a restriction site and a DNA sequence of CNBD or GFP-mutant with 
a length corresponding to the amplification temperature.  
 
PCR fragments were run on a 1% agarose gel prepared on TAE puffer (40 mM 
Tris, 0.1 mM EDTA, 1 mM (CH3COO)Na, pH=8.54) using the same as a 
running puffer. DNA was purified directly from the gel using Qiaquick Gel 
Extraction Kit according to the manufacturer protocol. The DNA fragments 
were then cut using the appropriate restriction enzymes and subcloned into 
pcDNA3 expression vector for mammalian cell expression, pVL1393 for insect 
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cells or pET3d for bacterial expression. For protein purification from insect cells 
or bacteria, a sequence encoding for a hexahistidine tag was inserted into the 
constructs directly at the N-terminus using oligonucleotides  
5’-GATCCATGCATCATCATCATCATCATGGTATGGCTAGCT-3’ and  
5’-CTAGAGCTAGCCATACCATGATGATGATGATGATGCATG-3’.  
Cloning of PCR fragments or oligonucleotides was performed by ligation of the 
cut fragments into the restriction sites of the vector for 20 min at room 
temperature using T4 DNA ligase. 
 
The ligation mix was, next, introduced into competent E. coli XL1-Blue bacteria 
using a KCM buffer: 15 µl ligation mix, 65 µl water, 20 µl 5x KCM buffer, 100 
µl competent cells (competence 1x106 - 1x107 colonies/µg DNA), incubated 20 
min on ice, 10 min at room temperature, shaken 50 min at 37°C (Thermomixer 
5436, Eppendorf) with 1 ml added LB medium and plated on a selective LB-
medium plate, containing 1.5 % agar and 100 µg/ml ampicillin. 5x KCM buffer 
was prepared as follows: 150 mM CaCl2, 250 mM MgCl2, 500 mM KCl. LB 
medium was sterilized by autoclaving ex tempore  (Varioklav) and contained 
(m/v): 1% NaCl, 1% trypton and 0.5% yeast extract. Bacterial colonies were 
grown overnight and checked for the presence of the cloned construct by 
plasmid DNA isolation (Qiagen Plasmid Mini Kit) with subsequent restriction 
analysis. Positive colonies were then grown overnight in 200 ml LB medium 
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plus 100 µg/ml ampicillin and used for plasmid DNA purification (Qiagen 
Plasmid Maxi Kit). 
 
Concentration of plasmid DNA was calculated from the light absorption at 260 
nm measured in spectrophotometer with 1 cm path length (Shimadzu). 
Absorption of 1 corresponds to a plasmid DNA concentration of 50 µg/µl.  
  
2.1.2   Protein purification 
 
Sensor proteins were expressed in and purified from either insect Spodoptera 
frugiperda Sf9 cells or E.coli BL21-DE3.  
Insect cells were grown at 27°C in TC100 medium supplemented with 10 % 
fetal calf serum (FCS), 4 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml 
streptomycin. The construct of interest cloned into pVL1393 vector was 
expressed using the baculovirus system (Baculogold, Pharmingen). Cells were 
washed twice with chilled phosphate buffered saline (PBS), resuspended in 
buffer A (5 mM Tris buffer, pH=7.4), supplemented with 0.1 mM benzamidine 
and 0.1 mM phenylmethylsulphonylfluoride (protease inhibitors). Cell 
membranes were then disrupted by 20 s Ultra-Turrax T8 (IKA Labortechnik) 
and centrifuged at 40000 g (Beckman Ultracentrifuge LE70, Ti70 rotor). Cell 
lysates were purified by Ni-NTA chromatography (Qiagen) according to the 
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manufacturer’s instruction. Buffer A was used at the washing step and for 0-100 
mM imidazol gradient preparation. 
For bacterial expression competent BL21-DE3 cells were transformed with 
sensor constructs in pET3d vector. Bacteria were grown at 37°C to achieve an 
optical density of 0.6-0.8 measured at 600 nm, and protein synthesis was 
induced by addition of 0.5 mM isopropyl-ß-D-thiogalactopyranosid. Next, 
proteins were expressed for 18 h at 22°C. Bacteria were centrifuged for 10 min 
at 5000 rpm (Beckman Avanti J-25, JA-14 rotor), washed once with buffer A 
and resuspended in the same buffer plus protease inhibitor cocktail. Cell walls 
were then disrupted by 3 freeze/thaw cycles using liquid nitrogen and 5 min 
ultrasound treatment (Bandelin Sonopuls HD200). Cell lysates were centrifuged 
and processed for protein purification as described above. Fluorescent proteins 
were used for in vitro experiments directly after purification or frozen at -20°C 
for further studies (with no apparent change in functionality). 
 
2.1.3  Cell culture and transfections 
 
HEK293, HEKβ1 (HEK293 cell stably expressing 0.4 pMol/mg β1-AR) and 
TsA201 cells were grown in DMEM medium with 4.5 g/l glucose, 10 % FCS, 2 
mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C and 
7 % CO2. The cells were plated onto 24 mm glass coverslips in 100 mm dishes 
for live cell experiments or onto 150 mm Petri dishes for cuvette fluorometric 
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measurements and transfected with 10 µg or 30 µg, respectively, plasmid DNA 
using the calcium phosphate method. A precipitation mix for a 100 mm dish was 
as follows: water ad 1 ml, 2.5M CaCl2 50 µl, plasmid DNA 10 µg (10 µl of 1 
µg/µl solution), 2x BBS buffer 500 µl. To transfect 150 mm dishes 2.5x 
amounts were used. The mixture was incubated 20 min at room temperature and 
applied onto the cells for 24 h at 37°C 5% CO2. 2x BBS buffer contained: 1.5 
mM Na2HPO4, 50 mM N,N-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid, 
280 mM NaCl, pH=6.95. All solutions used in cell culture were filter-sterilized. 
CHO and CHOA2B (CHO cells stably expressing adenosine A2B receptors) 
cells were maintained in DMEM/F12 medium with 1.0 g/l glucose, 10 % FCS, 2 
mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C and 
5 % CO2, split onto 24 mm coverslips and transfected by the same procedure.  
PC12 cells were grown in DMEM medium (37°C, 5% CO2) containing 1.0 g/l 
glucose, 5% FCS, 10% horse serum and other supplements as above. 
Transfection was performed by electroporation in PBS and using Gene Pulser 
(BioRad) at 250 V, 500 µF. Cells were then seeded onto coverslips and used for 
imaging experiments after 24 h. 
 
2.1.4   Primary cells 
 
Peritoneal macrophages were isolated from 10-12 week old FVB/N mice as 
described154, resuspended in PBS and immediately transfected by 
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electroporation using Gene Pulser at 250 V, 500 µF, seeded onto 24 mm glass 
coverslips and maintained in RPMI 1640 medium, 10 % FCS, 2 mM L-
glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (37 °C, 5 % CO2).  
Primary dissociated mouse hippocampus neurons were isolated from neonatal 
(P1) C57BL/6 mice and cultured as described previously with some 
modifications155. Hippocampi were dissociated by incubation for 20 min in 
Tyrode’s solution containing ispase (4.8 mg/ml), collagenase (1 mg/ml) and 
desoxyribonuclease I (0.8 mg/ml). Primary neurons were transiently transfected 
with the Nucleofector system (Amaxa, Köln). Briefly, 3 x 106 freshly 
dissociated cells were electroporated with 5 µg plasmid DNA and cells were 
plated on poly-L-lysine and Matrigel-coated glass slides (coating was performed 
with a few drops of 1 % solution for 1 h) in Neurobasal-A medium for 3-5 days 
(37 °C, 5 % CO2). 18 h after transfection, 5 µM cytosine arabinoside was added 
to prevent proliferation of glial cells. Neurobasal-A medium contains 10 % FCS, 
0.5 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. All 
animal procedures were approved by the responsible government authorities 
(Regierung von Unterfranken, protocol No. 621-2531.01-10/98 and 28/01). 
Bovine adrenal zona glomerulosa (ZG) cells (adrenal glands were obtained  
from a local slaughterhouse) attached to the adrenal capsule were digested with 
1 mg/ml collagenase in Tyrode’s solution and mechanically disaggregated as 
described156,157. Isolated cells were suspended in DMEM medium supplemented 
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with 10% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin. For 
microscopic measurements, cells were plated on glass coverslips at a density of 
10 000 cells/ml and after 2 days were infected with adenovirus encoding for 
cAMP biosensor Epac2-camps. Adenovirus was constructed in the laboratory of 
Dr. Stefan Engelhardt using AdEasy kit and manufacture’s protocol 
(Invitrogen). After tittering adenoviral concentrations by plague assays 
conducted on monolayer 293 cultures, a multiplicity of infection between 10 and 
50 was used to infect primary adrenal ZG cells 48 h prior to FRET-
measurements. 
Primary rat mesangial cells were isolated from rat kidney glomeruli158. 
Glomeruli were obtained from whole kidneys of newborn rats and were minced 
finely with a razor blade followed by sequential sieving through 125- and 75-µm 
pore-size metal sieves and then collected on a 22.5-µm pore size sieve. Cells 
were cultured in RPMI 1640 medium, containing 20% FCS, 2 mM L-glutamine, 
0.1 mM sodium pyruvate, 5 mM HEPES buffer, pH 7.2, 100 units/ml penicillin, 
100 µg/ml streptomycin, 0.1% non-essential amino acids, and 0.1% growth 
supplements (5 µg/ml insulin, 5 µg/ml transferrin, 5 ng/ml sodium selenite). The 
cells were maintained at 37 °C and 5 % CO2 and transiently transfected with the 
Nucleofector system using the Primary Smooth Muscle Cell Kit (Amaxa, Köln). 
Briefly, 5 x 106 cells were electroporated with 5 µg PDE5 sensor plasmid DNA 
and immediately plated onto sterile glass slides. 18-24 h after transfection cell 
imaging experiments were performed.  
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2.1.5   Fluorescence measurements in vitro 
 
TsA201 cells 24 h post-transfection were washed thrice with chilled PBS, 
scraped from the plate and resuspended in buffer B (5 mM Tris-HCl, 2 mM 
EDTA, pH = 7.4). After disruption with an Ultraturrax device for 40 s on ice and 
20 min centrifugation at 80000 rpm (Beckman Opima TLX ultracentrifuge, TLA 
120.2 rotor), fluorescence emission spectra of the supernatant (excitation at 436 
nm, emission range 460-550 nm) were measured with a fluorescence 
spectrometer LS50B (Perkin Elmer) before and after addition varying cAMP, 
cGMP, AMP or ATP  concentrations. Saturation curves were plotted using 
KaleidaGraph 3.0.5 software (Abelbeck). 
For high throughput chemical mapping of CNBDs, fluorescent proteins purified 
from E.coli were diluted in buffer B to 50 nM concentration and pipetted onto a 
black 96-well plate, 98 µl per well. 2 µl of cyclic nucleotide analogue water 
solution were then added and the FRET ratios were measured using a MITRAS 
plate reader (Berthold Technologies). The data were analyzed by Microsoft 
Excel and Origin 6.1 software (Microcal). Concentration-response dependences 
for each substance were plotted using KaleidaGraph.    
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2.1.6   Fluorescence measurements in live cells 
 
For fluorescent microscopy and cell imaging glass coverslips with adherent 
cells were transferred to the experimental chamber in buffer C (144 mM NaCl, 5 
mM KCl, 1 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, pH = 7.3) at room 
temperature and placed on a Zeiss Axiovert 200 inverted microscope equipped 
with an oil immersion 63x Plan-Neofluar objective, beam splitter 505 DCXR 
and a CoolSNAP HQ CCD-camera (Visitron Systems, Puchheim, Germany). 
Samples were excited with light from a polychrome IV (TILL Photonics, 
Planegg, Germany). FRET was monitored using MetaFluor 5.0 software 
(Visitron Systems) as the emission ratio at 535 ± 20 nm and 480 ± 15 nm upon 
excitation at 436 ± 10 nm. The imaging data were analyzed by MetaMorph 5.0 
(Visitron Systems) and Origin software, corrected for spillover of CFP into the 
535 nm channel (57 % of the measured CFP fluorescence as calculated from the 
cells expressing CFP only), direct YFP-excitation and acceptor photobleaching 
to give a corrected ratio YFP/CFP. To study agonist-induced changes in FRET, 
cells were continuously superfused with buffer C plus agonist solutions. For 
local stimulation of a cell, patch pipettes filled with the respective agonists were 
accurately positioned onto the plasma membrane by a manipulator (Patchman, 
Eppendorf). To avoid free agonist diffusion along the membrane, cells were 
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continuously superfused with laminar flow of buffer C (coming from perfusion 
system) in the direction opposite to the pipette.  
In fluorometric detection mode the microscopy was performed by placing cells 
plated on coverslips on a Zeiss inverted microscope (Axiovert 200) with an oil-
immersion x100 objective, dual-emission photodiode system and a polychrome 
IV (both TILL Photonics). FRET ratios were measured as the ratio of the YFP 
and CFP emission intensities at 535 ± 15 and 480 ± 20 nm (beam splitter DCLP 
505 nm) upon excitation at 436 ± 10 nm (beam splitter DCLP 460 nm). The YFP 
emission upon excitation at 480 nm was recorded at the beginning of each 
experiment to subtract direct excitation of YFP (6 % of the measured YFP 
fluorescence as calculated from the cells expressing YFP only and excited at 436 
nm). Spillover of CFP into the 535-nm channel (80%, measured as described 
above; spillover of YFP into the 480-nm channel was negligible) was subtracted 
to give a corrected FRET ratio.  
FRET between CFP and YFP was also confirmed by donor dequenching after 
acceptor photobleaching. YFP (acceptor) bleaching was achieved by 5 min 
illumination at 480 nm. CFP fluorescence was recorded (436-nm excitation) in 
short intervals during the bleaching process (using the dual-wavelength protocol) 
to determine the resultant increase of CFP fluorescence. To study agonist-
induced changes in FRET, cells were continuously superfused with buffer C and 
agonist was applied using a computer-assisted solenoid valve–controlled rapid 
superfusion device (ALA-VM8, ALA Scientific Instruments) (solution exchange 
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5–10 ms). Signals detected by avalanche photodiodes were digitalized using an 
AD converter (Digidata1322A, Axon Instruments) and stored on a personal 
computer using Clampex 8.1 software (Axon Instruments).
 
2.1.7   Biochemical techniques 
 
VASP phosphorylation. After 3 days in culture the medium of zona 
glomerulosa cells was replaced by serum-free DMEM for 12 h and cells were 
incubated for 1 h with 10 µM forskolin, 10 nM ANP and 10 nM ACTH 1-24 
peptide, then the media was collected for aldosterone radioimmuno assay (RIA) 
and cells were harvested in SDS gel loading buffer (at 95 °C). PKA activity in 
the cells was analyzed by Western blot using the phosphorylation of the well-
known PKA and PKG substrate VASP detected by monoclonal anti-phospho 
(Ser239) mouse antibody159.  Equal loading was controlled by Ponceau-S 
staining of the membrane and by incubation of the stripped membranes with 
non-phospho VASP antibody. For visualization of the signal, goat anti-mouse 
IgG conjugated with horseradish peroxidase was used as secondary antibody 
(dilution 1:5000), followed by ECL detection.  
In the case of mesangial cells, the media was replaced with serum free DMEM 
for 12 h and they were stimulated for 5 min with 5 nM ANP, 10 µM SNP or 10 
µM isoproterenol with subsequent addition of the SDS loading buffer and 
Western blot analysis.  
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Aldosterone RIA. Aldosterone concentration in the culture medium of ZG cells 
was determined by RIA using a commercially available aldosterone kit (DPC 
Bierman) according to manufacture’s instruction. 
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2.2   Materials 
1. 
 
  
Bacteria strains 
E. coli XL1-Blue 
E.coli BL-21 DE3 
 
 
Stratagene 
Stratagene 
2. Plasmid vectors 
pcDNA3.1 
pVL1393 
pET3d 
pcDNA3-PKA-RII-CFP 
pcDNA3-PKA-CAT-YFP 
pEYFP 
pECFP 
pcDNA3-NPRA receptor 
 
 
Invitrogen 
Invitrogen 
Novagen 
M. Zaccolo, Padova 
M. Zaccolo, Padova 
Clontech 
Clontech 
M. Kuhn, Würzburg 
3. Template cDNA 
Epac1  
Epac2 
GKI 
PDE2 
PDE5 
 
 
H. Rehmann, Dortmund 
A. Wittinghofer, Dortmund 
S. Gambaryan, Würzburg 
J. Beavo, Washington 
C. Arkona, Leipzig 
4. Oligonucleotides 
 
MWG Biotech GmbH, Ebersberg 
5.  Chemicals 
ACTH 1-24 
Adenosine 
 
Sigma 
Sigma 
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AMP 
cAMP 
ANP 
ATP 
Agar 
Agarose 
Alprenolol 
Ampicillin 
Benzamidine 
Bisoprolol  
N,N-bis-(2-hydroxyethyl)-2-
aminoethanesulfonic acid  
Bradford reagent 
CaCl2 dihydrate 
Carvedilol 
(CH3COO)Na 
Collagenase 
Cytosine arabinoside 
Disoxyribonuclease I 
Disoxyribonucleotides (dNTPs) 
DNA ladders 
EDTA 
EHNA 
Ethanol  
Forskolin 
cGMP 
HEPES 
ICI 118.551 
Imidazole 
Sigma 
Sigma 
Sigma 
Sigma 
Gibco BRL 
Peqlab 
Sigma 
Applichem 
Sigma 
Merck 
 
Sigma 
Biorad 
Merck 
Stefan Engelhardt, Würzburg 
Merck 
Sigma 
Sigma 
Sigma 
Eppendorf 
New England Biolabs 
Merck 
Sigma 
J.T. Baker 
Sigma 
Sigma 
Roth 
Sigma 
Roth 
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Insulin 
Isopropanol 
Isopropyl-ß-D-thiogalactopyranosid 
Isoproterenol 
Ispase 
KCl 
Metoprolol 
MgCl2 
NaCl 
Non-essential amino acids 
Parathormone 
Phenylmethylsulphonylfluoride 
Ponceau-S 
Selenite 
Sodium pyruvate 
Transferrin 
Tris 
Trypton 
Yeast extract 
 
Sigma 
J.T. Baker 
Applichem 
Sigma 
GibcoBRL 
Sigma 
Applichem 
Merck 
Applichem 
Sigma 
Bachem 
Sigma 
Serva 
Sigma 
Sigma 
Sigma 
Merck 
Applichem 
Applichem 
6. Cyclic nucleotides (cAMP, cGMP) 
and their analogues for plate 
reader experiments (see Table 1) 
 
Biolog Life Science Institute, 
Bremen 
7. Enzymes and kits 
PKA catalytic subunit 
Pfu DNA-polymerase 
Restriction enzymes 
T4 DNA-ligase 
 
Cornelius Krasel, Würzburg 
Promega 
New England Biolabs 
Promega 
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Qiagen DNA-Maxiprep 
Qiagen Plasmid Mini Kit 
Qiaquick Gel Extraction Kit 
Ni-NTA protein purifucation kit 
Baculovirus expression system 
Baculogold 
Western blot ECL detection kit 
Aldosterone RIA kit 
Qiagen 
Qiagen 
Qiagen 
Qiagen 
 
Pharmingen 
Amersham 
DPC Biermann 
8.  Cell culture  
DMEM, 4.5 % glucose 
DMEM/F12, 1% glucose 
Neurobasal-A medium 
RPMI 1640 
FCS 
Glutamine 
Horse serum 
Matrigel 
Penicillin/Streptomycin 
Poly-L-lysine  
TC100 
 
 
 
PAN 
PAN 
Gibco BRL 
PAN 
Invitrogen 
PAN 
Invitrogen 
Becton-Dickinson 
PAN 
Sigma  
Biochrom 
 
9.  Other materials 
Cell culture dishes and multiwells 
96-well reader plates  
Glass coverslips 24 mm 
Patch pipette capillaries  
Filter for sterile filtration FP30/0.2 
 
NUNC 
Costar 
Hartenstein 
Harvard Apparatus 
Schleicher&Schuell 
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3   Results  
 
This section is comprised of four distinct parts. The first two are dedicated to the 
novel cAMP biosensors and describe their development and biological 
applications. The last two parts describe the generation and applications of 
improved single-domain cGMP fluorescent probes.  
 
3.1 Development of cAMP biosensors 
3.1.1   Single binding domain of Epac2 as a backbone for a   
cAMP-sensor 
 
To develop a novel highly sensitive cAMP biosensor advantage was taken of 
FRET as a tool to measure conformational changes in protein molecules. Based 
on the crystal structure of the regulatory domain of Epac2 152 and the predictions 
on a cAMP-induced conformational change, fusions of truncation mutants of 
Epac2 with YFP and CFP were generated to be able to monitor the cAMP-
driven structural rearrangement (Fig. 7A, B). Among the constructs containing 
either a single low affinity domain A or both low and high affinity (B) domains, 
none demonstrated a detectable change in FRET upon saturation with cAMP. 
Next, fusions of a single high affinity B-domain were generated, which 
produced a decrease in FRET upon activation (Fig. 7A, B, C).  
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Fig. 7. Development of the single-chain cAMP biosensors based on a single binding 
domain of Epac2.  A. Schematic representation of the constructs designed to 
measure cAMP. These are fusion proteins, containing a sequence of the regulatory 
domain of Epac2 (encompassed by amino acids M1-E443, M1-K149, E29-K149, 
E285-E443, E285-Q454 et c.) fused to YFP and CFP. A relative change in FRET 
measured in CHOA2B cells upon full receptor activation (with adenosine, 100 µM) is 
presented by + signs (significance of one, two, three +). Under each of the constructs 
the restriction sites are marked which were used to obtain a fusion construct. B. 
Crystal structure of the whole regulatory domain of Epac2152. Positions of fluorophore 
insertions are marked blue and labelled. C. Structure of a single high affinity binding 
domain B of Epac2 with positions indicated for fusions giving functional biosensors. 
D. The principle of the cAMP biosensor. cAMP induced conformational change 
determines a decrease in FRET between CFP and YFP.   
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Here CFP and YFP sequences were inserted directly on the α-helices B (at E 
285) and α6 (the so-called hinge helix, at E443) covering the phosphate binding 
cassette depicted in blue (Fig. 6C). In this case, it was possible to achieve an 
efficient initial FRET-signal (high emission of YFP upon CFP excitation), 
indicating a close spatial proximity of the fluorescent proteins (Fig. 7D). This 
signal underwent a dynamic change in presence of cAMP indicative of a cAMP-
induced conformational change, moving the described α-helices and the GFP-
variants fused on them apart from each other and resulting in a decrease of 
FRET (Fig. 7D). The first functional construct of the Epac2 binding domain B 
contained a sequence E285-E443 of Epac sandwiched between YFP and CFP 
and was called Epac2-camps (camps for cAMP sensor). To further characterize 
the fluorescent properties of the sensor, dynamic changes in cAMP were 
measured in vitro and in live cells.  
Expression of Epac2-camps in E.coli gave a highly soluble fluorescent protein, 
which was purified using the Ni-NTA method. The spectra of the purified 
protein demonstrated a high efficiency of FRET between CFP and YFP upon 
excitation at 436 nm (Fig. 8A). The FRET peak at 525 nm was reduced 
concentration-dependently by addition of cAMP, accompanied by a 
simultaneous increase in CFP fluorescence. The maximal change in FRET ratio 
observed in this case was over 40%, which is suitable for effective 
measurements in live cells (Fig. 8A). To compare the novel biosensor with the 
previously used technique based on PKA  
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Fig. 8. Measuring cAMP by Epac2-camps. A. Fluorescent spectra of Epac2-camps 
purified from E.coli. Growing cAMP concentrations lead to a progressive decrease in 
FRET. Representative spectra from 4 independent experiments are shown. B. In vitro 
kinetic measurements of Epac2-camps activation by cAMP compared to the PKA-
based sensor using proteins purified from Sf9 insect cells at 50 nM concentration.  
Epac2 demonstrates a rapid change in FRET at different cAMP concentrations, 
whereas the speed of PKA dissociation decreases at lower cAMP. Representative 
traces from 4 independent experiments are shown C. Kinetics of cAMP measured by 
Epac2-camps vs. PKA-probe in transiently transfected CHOA2B cells upon activation 
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of the A2B receptor with 100 µM adenosine. Data are mean ± S.D. are from 5 
independent experiments. 
 
dissociation (see 1.4) the kinetics of cAMP binding to both sensors were studied 
in vitro using the proteins expressed in insect cells and purified by the Ni-NTA 
method. Epac2-camps was switched on very rapidly (within 2 seconds, which is 
the limit of detection of our instrument) at different cAMP concentrations. PKA 
holotetramer, however, dissociated much slower, especially upon addition of the 
lower cAMP concentrations (Fig. 8B). This experiment demonstrates a much 
faster speed of Epac2-camps, which is limited solely by one-step binding of 
cAMP to the regulatory domain, whereas the dissociation of the PKA seems to 
be limited by multiple factors, such as cooperative sequential occupation of the 
4 cAMP binding sites and a series of conformational changes occurring prior to 
the dissociation of the complex (see 1.4 and 1.5). In this case one might get a 
delay when measuring cAMP, because the sensor is not capable of rapidly 
reporting a change in the concentration of the second messenger. Epac2-camps, 
however, provides a higher temporal resolution and increased sensitivity (Fig. 
8C), reporting the minor changes in cAMP as fast as never before. 
Comparing both approaches in live cells again demonstrated a higher 
performance of Epac2-camps compared to the PKA. Just a few seconds after the 
addition of adenosine to CHO cells stably expressing adenosine A2B receptors, 
Epac2-camps was activated reporting an increase in cAMP represented as a 
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decrease in FRET-ratio (Fig. 8C). The PKA-based sensor demonstrated a greater 
delay and a slower FRET-signal.  
Next, an attempt was undertaken to optimize the position of CFP and YFP 
insertion on the binding domain of Epac2 in order to improve Epac2-camps in 
terms of the amplitude of FRET-signal. Shortening of the helix B on the N-
terminus by 7 amino acids (fusion of YFP to E292) resulted in an increase of the 
amplitude without altering the kinetic properties of the sensor. Further N-
terminal truncations over the helix B (to M304, M310) did not significantly 
affect the signal (Fig. 7A, 9A). Taking longer sequences on the C-terminus (till 
Q454, E460 on the hinge helix of Epac2) dramatically decreased the amplitude 
of response in live cells, so that the optimal amino acid range to produce a 
highly sensitive sensor was determined to lie between E285 and E443. The best 
amplitude at almost 40% ratio change was achieved using the E292-E443 
construct (Fig. 9A). Fig. 9B demonstrates original traces of a cAMP 
measurement using this sensor in CHOA2B cells upon full activation of cAMP 
production. Like in a fluorometer cuvette (Fig. 8B), the sensor in live cells 
exhibited a rapid decrease in YFP and increase in CFP fluorescence, 
representative of the loss of FRET (Fig. 9B).  
The decrease in YFP/CFP ratio could be also monitored with high temporal and 
spatial resolution using cell imaging techniques, representing the rise in 
intracellular cAMP by false colours changing from red to blue (Fig. 9C). 
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Fig. 9. Optimization of the Epac2-based cAMP sensor by varying the positions of 
fluorophore insertion. A. Measurements of cAMP in transiently transfected CHOA2B 
cells upon full A2B-receptor activation using different Epac2-constructs. Ratio traces 
are presented from 4 experiments ± S.D. B. Original traces of YFP and CFP 
fluorescence from a representative (n=4) cAMP measurement using the E292-E443 
construct. A decrease in FRET upon activation is demonstrated. Conditions are as in 
A. C. On-line cell ratio images of the E292-E443 Epac2-sensor in CHOA2B cells at 
different times after agonist application (100 µM adenosine). Decrease in cAMP is 
represented here as a change of false colours from warm to cold ones over time.  
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By having created a series of fluorescent biosensors based on a single cAMP-
binding domain of Epac2 it was experimentally proven that a ligand-dependent 
conformational change exists and might play a role in the protein activation as 
predicted by previous studies (see 1.5). This biological mechanism could be 
used for monitoring cAMP in vitro and in live cells with high temporal and 
spatial resolution, improving traditional biochemical and previously developed 
FRET-approaches. The next question was, if this mechanism is the case for 
cyclic nucleotide-binding domains (CNBD) of other proteins and whether it 
might be possible to create biosensors on the basis of their structure.  
 
3.1.2   Sensors based on binding domains of Epac1, protein 
kinase A and cyclic nucleotide-gated channels   
 
Among the cAMP-binding protein family, there is another isoform of Epac 
described, which is called Epac1 and contains only one high affinity cAMP 
binding site30,160,161. However, the crystal structure of this protein has not been 
solved. To create a FRET-biosensor based on Epac1, the sequence homologous 
to that of Epac2-camps (E157-E316 in Epac1) was fused between YFP and CFP 
(Fig. 10). This construct produced an extensive change in FRET as tested in 
CHOA2B cells (comparable with Epac2-sensors) and was termed Epac1-
camps.  
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Each regulatory subunit of PKA contains two cAMP-binding domains, one of 
which (the B domain) is supposed to have a higher affinity and to be occupied 
first in the presence of cAMP, whereas the A-domain has a lower affinity for 
cAMP, but interacts with the catalytic subunit and regulates its release after 
binding the second cAMP molecule (see 1.5). Sandwiching the two domains 
together between fluorophores did not yield any detectable change in FRET. 
However, fusion of CFP and YFP at different positions to the B-domain 
produced three functional sensors (V255-A416, M264-A416, M264-A403). The 
best one bears the sequence M264-A403 of the PKA and was termed PKA-
camps (Fig. 10). The third cAMP binding protein that could serve as a backbone 
for a biosensor is HCN2 channel, which contains a single CNBD of a known 
structure. To create a new fluorescent cAMP-probe based on HCN2 the GFP-
variants were inserted on different α-helices covering the CNBD. This led to 
three constructs with various amplitude of the signal, the best of which 
contained the sequence A467-K638 and was called HCN2-camps (Fig. 10).  
Next, the properties of the four camps based on different CNBDs were 
compared in live cells and in vitro. In the next series of experiments another Gs-
coupled receptor, namely β1-adrenergic receptor, was used to elevate 
intracellular cAMP levels. In transiently transfected HEKβ1-cells stimulated 
with isoproterenol the sensors demonstrated differences in the amplitude of the 
FRET-signal (Fig. 11A). The ratio changes for all sensors in these cells were 
slightly   smaller   than   in   CHOA2B,   but   the   relative   change  in ratio was 
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Fig. 10. Creating cAMP biosensors based on PKA, Epac1 and HCN2. Schematic 
representation of the constructs (left), relative amplitude of the signal (middle) and 
corresponding crystals structures of PKA and HCN2 with positions of fluorophore 
insertion labelled (right) are shown. All experiments were performed as described in 
Fig. 7 
 
comparable, favouring Epac1-camps as a sensor which exhibits the largest 
magnitude of the signal (Fig. 11A). This indicator was tested in cell imaging 
experiments and demonstrated a high spatial resolution, allowing visualizing 
cAMP changes in different regions of the cell (Fig. 11B). Interestingly, different 
probes not only revealed various amplitudes of the signal, but also differences in 
the duration of the so-called plateau achieved within some tens of seconds after 
the addition of the agonist and indicating the saturation of a sensor. This fact 
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could be due to differences of the binding affinities of cAMP to the four sensors. 
Therefore, additional in vitro experiments were performed to measure an 
effective cAMP concentration producing a 50% change in the FRET-signal 
(EC50).  To  do  this  the  camps  were  transiently  expressed  in  TsA201  cells, 
cytosol was prepared by lysis and centrifugation, and different concentrations of 
cAMP were added to the cytosol in a fluorometer cuvette. 
 
Fig. 11. Comparing  biosensors based on four different CNBDs in their ability to 
report changes in cAMP in live cells. A. FRET changes in HEKβ1-cells transiently 
expressing the indicators were measured fluorometrically upon addition and 
withdrawal of 1 µM isoproterenol (Iso). The traces are dissected to better compare 
the kinetics of the sensors. B. Cell imaging experiments performed using Epac1-
camps as described in Fig. 9C. 
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Indeed, the different sensors exhibited different affinities for cAMP (Fig. 12), 
which is in line with the data on differences in affinities of the CNBDs of Epac1 
and 2 161. HCN2-camps demonstrated the lowest affinity for cAMP, which might 
explain the obvious absence of the plateau in live cell experiments (not shown). 
On contrary, the longest plateau was observed with Epac2-camps, which has the 
highest affinity (Fig. 12). In this case the intracellular cAMP concentrations 
exceeded the upper measuring limit of the indicator. This might be improved by 
using the sensors with lower affinities for cAMP (e.g. HCN2-camps).  
 
Fig. 12. Comparing the binding properties of the cAMP-sensors based on four 
different CNBDs.   Measurements were performed with the cytosol of transiently 
transfected TsA201 cells. The representative concentration-response curves are 
presented (n=3). The EC50 values were as follows: Epac2-camps - 0.92 ± 0.07 µM, 
PKA-camps – 1.88 ± 0.37 µM, Epac1-camps – 2.35 ± 0.42 µM, HCN2-camps – 6.00 
± 0.52 µM. Data are expressed in means ± S.D.  
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In the same system, the selectivity of Epac2-camps towards other nucleotides, 
which are present in cells, was tested, demonstrating that cGMP, ATP and AMP 
were recognized only weakly (Table 1). 
 
Table 1. Affinities of Epac2-camps for different nucleotides measured  
as in Fig. 12 (n=3, means ± S.D.) 
 
Nucleotide Affinity for Epac2-camps (EC50) 
cAMP 0.92 ± 0.07 µM 
cGMP 10.6 ± 0.4 µM 
ATP 2.5±0.4 mM 
AMP >10 mM 
 
 
In summary, the cAMP-sensors that were generated using the binding domain of 
different proteins as a backbone demonstrate different affinities for cAMP, and 
together also allow to measure the concentration of this second messenger in a 
broad physiological range from ~ 100 nM to ~ 30 µM. Depending on the 
intracellular cAMP concentrations in a given type of cells, different camps or 
their combinations might be applied to cover the dynamic range of the 
signalling. 
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A special case of a CNBD is the A binding site of PKA. It has a dual role in the 
activation of the holotetrameric complex serving as a binding partner for both 
cAMP and the catalytic subunit, mediating the release of the latter when cAMP 
is bound in both B and A sites (see 1.5). The interface of regulatory-catalytic 
subunits interaction has a complicated architecture involving over 10 key amino 
acid residues of contact in the helical and phosphate-binding domains. The most 
crucial helical interface is located on the helix A (Fig. 5) 24. Fusion of the A-
domain sequences of the PKA to CFP and YFP resulted in a generation of a 
single functional sensor (Fig. 13A). Only the fusion protein containing the helix 
A (Q139-M264, Fig. 13B) was functional and revealed an interplay between 
cAMP and the catalytic subunit on the binding site A of the PKA. Fluorescent 
spectra of this protein demonstrated an initial FRET between the fluorophores 
that slightly decreased upon addition of cAMP. When the purified catalytic 
subunit was added to the cuvette this initial FRET-signal was significantly  
elevated and again was greatly reduced upon addition of cAMP (Fig. 13C).  This 
behaviour of the A-domain sensor demonstrated binding of the catalytic subunit 
with a change of conformation and the reversal of this structural rearrangement 
upon binding of cAMP, which serves as an allosteric competitor of the catalytic 
subunit. Thus, it was possible to generate a fluorescent sensor, which reports the 
binding of catalytic subunit to the A-domain of the PKA and its concurrent 
displacement by cAMP. Such an indicator supports the scenario of PKA-
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complex activation proposed based on its crystal structure and allows to further 
study the molecular dynamics of PKA.  
 
 
Fig. 13. Generating a FRET-sensor based on a single A binding site of PKA. A. 
Structure of the constructs and relative change in FRET upon addition of cAMP to the 
protein expressed in TsA201 cells as measured with cytosolic preparations in vitro. 
B. Crystal structure of the A-domain of PKA with the positions of fluorophore insertion 
labelled. C. Fluorescent spectra taken as described in Fig. 7A without the ligand and 
catalytic subunit (black), after addition of 5 nM of catalytic subunit (red) and after 
addition of cAMP to the complex of the sensor with the catalytic subunit (green).  
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In summary, a series of FRET-based biosensors for cAMP was created, which 
now allow measuring this second messenger in vitro and in live cells with high 
temporal and spatial resolution. All known cAMP binding domains were used as 
a backbone for fluorescent sensors and demonstrated a decrease in FRET upon 
binding of the ligand. Therefore, this study proved the previously suggested 
conformational change, which was proposed on the basis of X-ray crystal 
structure analysis as a ubiquitous mechanism of cAMP binding domain 
activation. This conformational change could be used to measure dynamic 
changes of cAMP by means of FRET. 
 
3.2   Applications of cAMP sensors 
 
After having produced a variety of novel fluorescent probes for cAMP, it was 
decided to apply them to investigate physiologically relevant aspects of cAMP 
signaling. First, spatio-temporal dynamics of cAMP diffusion were studied in 
different cell types. Secondly, real-time monitoring of PDE2 activity in 
aldosterone-producing cells was performed. Further on, the sensors were applied 
for screening of the cAMP-activating anti-β1-receptor antibodies in heart failure 
patients. Finally, using the family of fluorescent indicators chemical 
mechanisms of cAMP-binding domain activation in terms of conformational 
change were studied.  
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3.2.1  Spatio-temporal dynamics of cAMP signaling 
 
It has been argued over decades, whether cAMP acts in cells as a freely 
diffusing second messenger or whether such signals are more localized, for 
example via activation of local pools of PDE activity162. In line with this 
hypothesis, PKA-dependent β2-adrenergic mediated stimulation of L-type 
calcium channels in primary hippocampal neurons has been suggested to occur 
in spatially restricted signaling complexes163. In this part of the study it was 
decided to investigate the intracellular distribution of cAMP signals in different 
cells using the novel Epac-camps as a biosensor.   
To assess the spatio-temporal aspects of cAMP signaling primary hippocampal 
neurons were transfected with Epac1-camps. The Epac1-camps expressing cells 
were then stimulated with the β-adrenergic agonist isoproterenol (50 nM) 
delivered locally with a patch pipette under constant perfusion in the opposite 
direction in order to prevent agonist diffusion on the cell surface. This local 
stimulation resulted in a rapidly spreading change in the FRET-signal, reflecting 
a rise in cAMP propagating from the site of stimulation through the whole 
neuron on the scale of a few hundred milliseconds (Fig. 14A).  Rapidly 
spreading cAMP-signals were also observed with Epac1-camps in other cells, 
including mouse peritoneal macrophages stimulated locally with isoproterenol   
(Fig. 14D).  In  CHOA2B cells as well  as  in  PC12 cells with endogenous 
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Fig. 14. cAMP gradients in murine primary hippocampal neurons and peritoneal 
macrophages. A. Neurons transiently transfected with Epac1-camps were stimulated 
by gently touching with a patch pipette filled with 50 nM isoproterenol (arrow in inset) 
under a constant perfusion to avoid agonist diffusion along the membrane. FRET-
responses were measured in different regions of the cell away from the site of 
stimulation. Representative experiment (n=5). Scale bar, 10 µm. B. Gradients in 
neurons transfected with the tetrameric PKA-indicator and stimulated with 1 µM 
isoproterenol (n=5) demonstrate lower amplitude and speed of cAMP propagation. 
Scale bar, 10 µm. C. Calculated cAMP-gradient propagation speed measured in 
hippocampal neurons with Epac1-camps in A (37.9 ± 2.2 µm/s, diffusion constant 
478.2 ± 23.0 µm2/s ) and PKA-system in B (2.1 ± 0.1 µm/s).D. cAMP gradients in 
murine peritoneal macrophages. The cells were transfected with Epac1-camps and 
stimulated with 10 µM isoproterenol delivered locally by a patch pipette (stimulus, 
white arrow). FRET-responses are demonstrated for two different regions of the cell. 
Representative experiment (n=4). Scale bar, 5 µm.  
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adenosine A2A-receptors164 similar spatial patterns of cAMP-signaling were 
observed in response to adenosine. Another cell type tested were HEK293 cells 
stably expressing parathyroid hormone receptors, where the local delivery of the 
ligand led to a cAMP-gradient freely propagating through the whole cell.  
Measuring these rapidly propagating FRET-changes in many cells made it 
possible to calculate the speed of the cAMP gradient in neurons. To do so, the 
FRET-signals in different regions of the cell (Fig. 14A) were fitted to a first-
order exponential function, and the intersection of the fit with the baseline was 
defined as the time of activation.  
To study the difference between cAMP levels measured with Epac1-camps and 
the previously described tetrameric PKA-indicator, the latters was also studied 
in the same primary neuronal cells. In this case, the speed of cAMP-propagation 
(even at 1 µM isoproterenol, Fig. 14B) was ≈20-fold slower than that recorded 
with Epac1-camps (Fig. 14C). In addition, the PKA-sensor allowed recording in 
only a third of the transfected neurons compared to a ≈100% responsiveness 
with Epac1-camps and furthermore the PKA-sensor had a smaller signal 
amplitude than Epac1-camps.  
The speed of cAMP-gradients measured with Epac1-camps after local 
stimulation with 50 nM isoproterenol was calculated at almost 40 µm/s, from 
which a diffusion coefficient at 487 ± 23 µm2/s was derived. This is much faster 
than previously described for cells stimulated with neurotransmitters and 
measured using PKA subunits labeled with rodamine and fluorescein144. The 
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kinetics of cAMP propagation measured with Epac1-camps corresponds well 
with those estimated for cAMP using patch-clamp recording of cyclic 
nucleotide-gated channels (270 µm2/s)165 and with the diffusion coefficients 
calculated for cGMP (500 µm2/s)166 and free microinjected cAMP (780 
µm2/s)143.  cAMP signals recorded with Epac1-camps were uniformly 
distributed throughout hippocampal neurons, whereas PKA mediated signals 
such as β-adrenergic stimulation of L-type calcium channels were reported to be 
locally restricted, presumably due to formation of signaling complexes including 
receptors, G proteins adenylyl cyclases, PKA, effectors and phosphatases163. 
 
3.2.2   Real-time monitoring of phosphodiesterase activity of 
live cells 
    
In different kinds of primary cells (neurons and macrophages) as well as in 
intact cells expressing various Gs-coupled receptors such as A2B-adenosine, 
PTH, β2-adrenergic receptors no localized cAMP signals were observed, 
suggesting that cAMP behaves in those cells as a freely diffusing second 
messenger, propagating through the cells with very high speed. The so-called 
compartmentalization of the signaling or the access of cAMP to its intracellular 
targets appears to be regulated by certain isoforms of PDE through cAMP-
hydrolysis102. Little is known, however, about the kinetic properties of these 
enzymes in live cells and about the mechanisms responsible for the PDE-
dependent compartmentalization. For this reason, in the next part of the study 
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the PDE activity was directly measured in live cells using the developed cAMP-
sensors to better understand the role of PDEs in regulating cAMP-signaling. 
To monitor PDE activity in real-time, the novel cAMP biosensor was used in a 
physiological system. It seemed most interesting to analyze such a PDE that can 
be selectively activated by a specific stimulus and represents a predominant 
isoform in the cells of interest in order to avoid a possible interplay with other 
PDEs. Among the numerous PDEs, PDE2 has been characterized as a cGMP-
stimulated isoform hydrolyzing cAMP (see 1.1). In adrenal zona glomerulosa 
(ZG) cells PDE2 serves as a cGMP-stimulated effector of ANP to decrease 
cAMP-stimulated aldosterone secretion (Fig. 15). In the present study PDE2 
activity was measured in bovine adrenal ZG cells, where PDE2 is not only a 
predominant isozyme providing almost 100 % of PDE activity47, but also the 
unique cGMP-binding protein, because in contrast to rat ZG cells GK and 
cGMP-gated ion channels are not expressed in this cell type156.  
To test whether an Epac-based fluorescent indicator could be used to monitor 
PDE activity in these cells it was first investigated, how fast bound cAMP 
dissociates from the sensor. In case of slow dissociation this step might become 
time-limiting for the system, making correct measurements of PDE2 action 
impossible. After saturating purified Epac2-camps with 20 µM cAMP (with a 
fast on-rate of 2.0 ± 0.2 s), a high amount of purified catalytically active PDE 
(10 µM) was added to the cuvette to degrade unbound ligand.  
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Fig. 15. Experimental system for monitoring PDE2 activity. Signalling pathway in 
bovine adrenal ZG cells, which regulates aldosterone production. cAMP is produced 
by adenylyl cyclases (AC), which are activated by Gs-protein coupled receptors, e.g. 
ACTH- or β-adrenergic receptors, or directly by forskolin. cGMP-stimulated PDE2 
blocks aldosterone production by degrading cAMP after activation of ANP receptors, 
which contain a guanylyl cyclase domain (GC). EHNA - erythro-9-(2-hydroxy-3-
nonyl)-adenine – is a selective inhibitor of PDE2.  
 
cAMP depletion led to an immediate dissociation of the sensor-bound ligand 
fraction with an apparent half-life of 2.9 ± 0.3 s (Fig. 16). At a catalytic activity 
of the PDE-preparation used of 0.3 mol of cAMP/s/mol of PDE, degradation of 
cAMP in the cuvette can be estimated to occur with a half-life of ~3 s. Since 
cAMP depletion in this experiment is limited by the speed of PDE-mediated 
cAMP-hydrolysis, the real kinetics of cAMP dissociation from the sensor are 
difficult to estimate, but must be much faster than the speed of increase of the 
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FRET signal. This indicates that Epac2-camps could be used to monitor PDE2 
activity provided that the latter process occurs with a half-life above 2 s.  
 
Fig. 16. Measuring dissociation of cAMP from Epac2-camps. 40 nM solution of 
purified protein (600 µl) was saturated with 20 µM cAMP and the bovine heart PDE at 
10 µM final concentration was added to the cuvette leading to a rapid dissociation of 
the bound ligand. Representative experiment (n=4). 
 
To monitor PDE2 activity in primary adrenal ZG cells, they were transfected 
with Epac2-camps using adenovirus, because these cells are not transfectable by 
other known techniques (Fig. 17B). After 2-3 days in culture single-cell 
microscopic measurements were performed. cAMP degradation by PDE was 
monitored as an increase of the FRET signal.  Stimulation of adenylyl cyclase 
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by addition of 10 µM forskolin resulted in a substantial increase of intracellular 
cAMP (monitored as a decrease in FRET-ratio) from basal sub-micromolar 
levels up to a plateau (Fig. 17A), suggesting saturation of the sensor (≈ 20 µM). 
Next, PDE2 was activated in the cells by stimulation with ANP. A very rapid 
increase in the FRET-signal was observed, demonstrating a fast degradation of 
cAMP by PDE2. After a few seconds delay, PDE2 apparently became active and 
hydrolyzed the majority of intracellular cAMP with a half-live (t0.5) of 15.5 ± 0.9 
s (Fig. 17A). This time is at least 5 times higher than the speed of cAMP 
dissociation from purified Epac2-camps in vitro (Fig. 16), suggesting that PDE2 
activity can be accurately monitored as a time-limiting process. Using this 
protocol a concentration-response dependence of the ANP-effect on PDE2 
activity was measured with a half-maximal response at 0.43 ± 0.02 pM ANP 
(Fig. 17C). Levels of intracellular cAMP measured in real-time with this system 
correlated well with the data of conventional biochemical experiments on 
aldosterone production and phosphorylation of VASP, a substrate of PKA and 
GK (Fig. 17D). In addition to the generally accepted concept that aldosterone 
production in adrenal cortex cells is critically dependent on cAMP levels, which 
are regulated by ANP-activated PDE2, it could thus be demonstrated that PDE2 
activity kinetically overcomes the forskolin-induced cAMP production, 
providing a mechanism to hydrolyze extensive amounts of the second messenger 
and thereby put aldosterone secretion under the control of the ANP-NO-cGMP 
axis. 
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Fig. 17. ANP inhibits forskolin-induced cAMP accumulation and aldosterone 
production in bovine adrenal zona glomerulosa cells.  A. Measuring cAMP in 
aldosterone-producing cells demonstrates a rapid action of PDE2. cAMP, which is 
produced in cells by stimulation with forskolin (Forsk), was rapidly (t0.5  15.5 ± 0.9 s) 
degraded upon addition of ANP, presumably via cGMP-mediated activation of PDE2. 
Intracellular cAMP was monitored microscopically as a FRET-ratio YFP/CFP in single 
cells, infected with Epac2-camps adenovirus (YFP image in B) and superfused with 
different compounds. A decrease in the ratio represents an increase in cAMP.  
Representative experiment (n=5). C. Concentration-response dependence of the 
ANP effect on PDE2 activity as measured with a FRET-based system as in A. Data 
of 5 experiments are presented ± S.E. EC50 value is 0.43 ± 0.02 pM, Hill slope – 
2.9±0.4. D. ANP inhibits aldosterone production and PKA activity. Bovine ZG cells 
were stimulated with 5 µM forskolin, 10 nM ANP, or a combination of forskolin with 
ANP. After 1 h of incubation, the culture medium was collected for aldosterone RIA 
and cells were harvested for Western blot analysis of the phosphorylated PKA-
substrate P-VASP. Results are mean ± S.E. of three different experiments. *, 
Significant differences (p < 0.05) compared to control values. +, significant 
differences (p < 0.05) compared to forskolin stimulated values. 
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Next, the activity of PDE2 was investigated under different conditions including 
stimulation of the cells via a physiologically relevant GPCR.  To further 
characterize PDE2 activity in ZG cells, we used its specific inhibitor EHNA, 
which at micromolar concentrations allows to selectively block the enzyme, 
inhibiting other PDEs at more than 100 µM only partially167. When applying 
EHNA to the cells under basal conditions, little effect on cAMP could be 
observed even at 100 µM (Fig. 18A), indicating that basal PDE2 activity in 
unstimulated ZG cells is very low. In contrast, applying a saturating 
concentration of ANP activated PDE2, which led to a decrease in cAMP, even 
though this effect was not as prominent as after forskolin stimulation (Fig. 18A), 
corresponding well with the functional data on aldosterone production (Fig. 
16D). ACTH as a natural ligand capable of stimulating aldosterone secretion 
induced a slow cAMP-accumulation, which could be fully and rapidly blocked 
(t0.5 13.0 ± 3.2 s) by ANP (Fig. 18B). This effect was inhibited by the specific 
PDE2-inhibitor EHNA, applied in addition to ACTH and ANP. Interestingly, 
the ACTH effect on cAMP production in this case was much stronger. Similar 
effects have been previously observed for specific PDE3 and PDE4 inhibitors 
and adrenergic stimulation in cardiac myocytes100. Upon removal of the 
inhibitor, ANP-induced PDE2 activity was immediately restored and brought 
cAMP in cells down to the basal level. The t0.5 for this restoration of PDE2 
activity was 18.3 ± 1.9 s, which is comparable with the speed of ANP-effects in 
presence of forskolin (Fig. 17A).  
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Fig. 18. Real-time monitoring of PDE2 activity under basal and agonist-stimulated 
conditions. A. Low basal PDE2 activity in ZG cells is demonstrated by the fact that 
EHNA, a specific PDE2 inhibitor, even at 100 µM caused only minor changes in 
intracellular cAMP. ANP (10 nM) alone exhibited a small stimulatory effect on 
intracellular cAMP. % change in ratio YFP/CFP is demonstrated. Representative 
experiments (n=4). B. ACTH-induced (10 nM) cAMP-accumulation is rapidly 
terminated by ANP-stimulated (10 nM) PDE2 action, which was fully blocked by 
EHNA (10 µM). Representative experiment (n=6). C. Isoproterenol-mediated 
activation of endogenous adrenergic receptors in ZG cells leads to cAMP 
accumulation. Rapid PDE2 activation kinetically overcomes cAMP production. 
Representative experiment (n=9). D. Concentration-response dependence of the 
EHNA effect on PDE2 activity demonstrated in C. Data of 3 experiments ± S.E. EC50 
value is 0.82 ± 0.16 µM, Hill slope 1.17. 
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PDE2 activity was 18.3 ± 1.9 s, which is comparable with the speed of ANP-
effects in presence of forskolin (Fig. 17A).  
EHNA has been demonstrated to reverse the inhibitory effect of cGMP-
dependent PDE2 on cAMP-stimulated calcium current in frog ventricular 
cardiomyocytes after isoproterenol treatment168. Therefore ANP and EHNA 
effects on β-adrenergic receptor-mediated cAMP production in ZG cells were 
studied. The β-adrenergic receptor agonist isoproterenol induced a cAMP signal 
that was again blocked by ANP-stimulated PDE2 (Fig. 18C). EHNA, 
comparable with the ACTH experiments, fully blocked PDE2 activity and 
together with isoproterenol further increased cAMP, exhibiting a half-maximal 
effect at ≈1 µM (Fig. 18D), which corresponds well with the previously 
measured constants157,159. Again, PDE2 recovery demonstrated rapid kinetics 
with a t0.5 of 19.8 ± 2.6 s (Fig. 18C).  
In summary, using the bovine adrenal cells as a model system, the monitoring of 
PDE activity in live cells was achieved. Taking advantage of the high expression 
of PDE2 in ZG cells and specifically stimulating it with ANP, which is 
responsible for physiological regulation of aldosterone production, it was 
possible to analyze real-time kinetics of cAMP hydrolysis by PDE2. An 
extremely fast action of PDE2 was observed, which allows to kinetically 
overcome forskolin-, ACTH- or β-adrenergic receptor-mediated cAMP-
accumulation, in order to fully block their effects on aldosterone production. 
Epac2-camps in this measuring system is capable of measuring PDE2 activity 
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due to a much faster ligand dissociation from the sensor (Fig. 16), compared to 
the speed of PDE2-mediated, time-limiting cAMP hydrolysis (Fig. 17A, Fig. 
18B,C). In contrast to classical biochemical studies where the activity of PDE is 
estimated on a scale of minutes, the real-time live cell experiments reveal that 
the endogenous PDE2 only needs 15-20 s to decrease intracellular cAMP from 
high micromolar (saturation of the sensor at ≈ 20 µM) to sub-micromolar (the 
lower detection limit of Epac2-camps at ≈ 100 nM) concentrations (Fig. 16A, 
17B,C). Such a high catalytic activity and rapid action of PDEs could be crucial 
for their physiological function to rapidly antagonize cAMP formation in cells 
and shut down its signaling. Extremely rapid PDE2-mediated cAMP degradation 
observed in the present experiments could also be important for 
compartmentalization of the cAMP signaling, which might be resulting from the 
much higher speed of PDE-catalyzed cAMP hydrolysis compared to the speed 
of cAMP production in living cells.   
 
3.2.3   Detection of anti-β1-receptor autoantibodies in cardiac 
myopathy patients 
 
Over the past two decades evidence has accumulated that functionally active 
autoantibodies targeting the human β1-adrenergic receptor (β1-AR) may play an 
important role in the development and clinical course of progressive cardiac 
dilatation and failure169. In this context, it became recently possible to 
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demonstrate that rats immunized against the presumably antigenic second extra-
cellular β1-receptor loop (100% sequence-identity between human and rat)170 
developed both, stimulating anti-β1-receptor antibodies (anti-β1-AR) and 
progressive dilated cardiomyopathy (DCM).171 Subsequent isogenic transfer of 
anti-β1-AR from immunized to healthy rats (in order to mimic autoantibodies) 
also transferred the disease and hence provided direct evidence for a cause-and-
effect relationship between stimulating anti-β1-AR antibodies and DCM in 
human-analogous animal model. To date, conventional methods do not allow to 
functionally detect anti-β1-AR with high sensitivity and temporal resolution. In 
the present study FRET was used to establish a novel technique to measure β1-
AR-induced cAMP signals in live cells.  
To determine the anti-β1-AR antibodies via receptor-induced signal propagation 
β1-AR-expressing cells (HEKβ1-cells) were transfected with Epac1-camps 
Before testing IgG from DCM-patients (and healthy control subjects) IgG 
isolated from previously characterized anti-β1-AR-positive rats with dilated 
immune-cardiomyopathy and isogenic control rats were used to establish the 
FRET-detection system171. None of the IgG from isogenic control rats affected 
cAMP levels in β1-AR expressing cells, whereas activating rat anti-β1-AR 
produced clear-cut signals and induced a rapid, more than 70%-loss in FRET, 
indicating an effective receptor activation. The onset of the response was 
delayed by some 100-150 s, which might indicate binding events (Fig. 19).  
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Fig. 19. Effects of rat IgG preparations 
on intracellular cAMP.  
IgG fractions from rats immunized 
against the 2nd extracellular loop of the 
human β1-AR (B) were tested on 
HEKβ1-cells transfected with Epac1-
camps compared to unimmunized 
animals to verify the reliability of the 
approach (A). FRET ratio traces are 
presented (% indicates a relative 
change in YFP/CFP intensity ratio, Iso-
isoproterenol). IgG concentration used 
in the assay was 0.13 µg/µl. The 
measuring buffer C in all anti- β1-AR 
experiments was supplemented with 50 
nM ICI 118.551 to block endogenous β2-
ARs. Representative experiments (n=6).  
 
These experiments with the animal sera suggested that the measuring system 
might be capable of detecting the presence of specific anti-β1-AR also in heart 
failure patients. 
Next, IgG-fractions isolated from n=55 previously antibody-typed DCM-
patients and n=20 healthy control subjects172 were re-analyzed by FRET. None 
of the IgG from healthy controls affected Epac-FRET (Fig. 20A), whereas IgG 
from all previously anti-β1-AR-positive judged DCM-patients induced a rapid 
loss of FRET, indicating receptor activation (Fig. 20A). In addition to all anti-
β1-AR-positive DCM subjects, IgG from 30 of 37 previously anti-β1-AR-
negative judged by immunofluorescence DCM-patients induced a modest but 
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significant increase in cAMP (Fig. 20A). The strength of the cAMP-signal in 
this group of sera was significantly lower than in the case of previously 
positive-judged samples (p<0.01, Fig. 20B).  
 
A B  
Fig. 20. Epac1-camps is able to detect 
None of the n=20 healthy control serums
live cells (left). Representative experime
judged by immunofluorescence anti-β1-
response (49.5 ± 3.8 % of maximal Iso
(n=18). IgG from 81% of anti-β1-AR-nega
significantly smaller increase in cAMP 
experiment (n=30). Quantifications are s
S.D. C. Concentration-response depende
IF- patients demonstrate differences in 
response is presented ± S.D. RepresentaC 
anti-β1-AR antibodies in DCM patients. A. 
 induces a visible cAMP-FRET response in 
nt (n=20). IgG from all patients with DCM 
AR-positive (IF+) elicit substantial cAMP-
-signal, right). Representative experiment 
tive patients (IF-) demonstrate a robust, but 
(30.3 ± 8.4 %, middle). Representative 
hown in B. Data is expressed in mean ± 
ncies of the IgG preparations from IF+ and 
maximal response. % of maximal cAMP-
tive experiments (n=4). 
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Analysis of the concentration-response dependencies for IgG from these two 
groups demonstrated that the low-activating IgGs even at higher concentrations 
did not increase cAMP levels as much as did the antibodies from the previously 
identified anti-β1-AR-positive patients (Fig. 20C), excluding the possibility of 
just lower titers and rather suggesting different mechanism of action at the 
receptor (e.g. activation of different epitopes on the receptor).  
The therapeutic strategies aimed at counteracting the action of anti-β1-AR by 
using receptor antagonists proved beneficial in DCM patients.172 Therefore the 
action of some clinically relevant drugs on autoantibody-induced cAMP signals 
was analyzed in the FRET-based system. Indeed, both β1-selective (bisoprolol, 
metoprolol) and unselective (alprenolol, carvedilol) beta-blockers largely 
suppressed the cAMP production (Fig. 21A,B). However, they produced only a 
partial effect resulting in maximally 60-80% cAMP-suppression (Fig. 21C). 
Despite being used in saturating concentrations (Fig. 21D) bisoprolol like all 
other drugs tested was not capable of fully reversing the cAMP-elevating effect 
of the antibodies. A possible explanation for this could be different mechanisms 
by which antibodies and antagonists act on the receptors. Antibodies induce 
receptor activation by binding at the extracellular loops169,173, distant to the 
ligand binding site. Therefore, further therapeutic strategies are needed to 
minimize autoantibody-induced cAMP-signalling in the heart.   
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Fig. 21. Beta blockers do not allow to fully reverse the cAMP-signal in β1-
autoantibody stimulated live cells. Neither unselective β-blockers alprenolol (Alpren) 
(A) and carvedilol (Carved), nor selective β-AR drugs bisoprolol (Biso) (B) and 
metoprolol (Meto) are able in saturating concentrations (3 µM) to suppress more 
than 80% of the IgG-response. Data (means ± S.D) are presented in C as calculated 
from 4 independent experiments. D. Concentration-response dependence for the 
blocking action of bisoprolol measured as in B. % of maximal effect is presented ± 
S.D (n=4). 
 
In summary, the novel technique based on measurements of the β1-AR-
antibody-induced cAMP signal using FRET allowed not only to achieve a high 
specificity (substantial cAMP-response in heart failure patients and absence of 
visible signal in healthy controls), but also to greatly improve detection of 
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functional autoantibodies in the group of DCM-patients, that were not detected 
by previously available techniques. These patients might have the anti-β1-AR 
against other epitopes than the 2nd extracellular loop of the receptor and were 
previously judged anti-β1-AR-negative140. The new method detects increases in 
cAMP via the receptor activation by anti-β1-AR from ~80 % of all DCM-
patients, supporting the hypothesis of β1-autoantibodies as an important 
mechanism in the development of DCM and heart failure169,174. This prevalence 
correlates well with the functional data obtained on isolated neonatal 
cardiomyocytes, where the antibodies from humans with DCM prolonged action 
potential duration and enhanced contractility175. 
  
3.2.3  Chemical mapping of the cAMP-binding domains in 
terms of the conformational change 
 
Development of the family of cAMP biosensors allowed to measure different 
aspects of the signaling by this second messenger. Different cAMP binding 
domains demonstrated similar activation properties, exhibiting a uniform 
conformational change upon binding of the ligand. Measurements by means of 
FRET suggest an increase in distance between helices A/B and C (hinge), 
covering the phosphate-binding cassette. This structural rearrangement was 
suggested to play a central role in cAMP-induced activation of Epac, PKA and 
HCN-channels (see 1.5). This part of the project was aimed at understanding 
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molecular mechanisms underlying the conformational change in different 
CNBD by using chemical compounds, which represented systematic changes of 
the lead structure of cAMP, allowing preferential binding to and activating of 
particular proteins. These substances are widely used in biochemical assays to 
selectively activate particular signaling cascades, but the detailed mechanisms of 
their action remain elusive. Here ten different cAMP derivatives were tested in 
terms of induction of the conformational change of different binding domains. 
The structure and known properties of the compounds are listed in Table 2.  
 
Table 2. Chemical structure and biological profile of cAMP-derivatives used in the 
current study. All compounds were from the BIOLOG Life Science Institute, home 
page (www.biolog.de).  
 
Systematic name  Chemical structure Biological properties 
cAMP 
 
Activates PKA, Epac 
and HCN-channels. 
See 1.1 
Adenosine-3’,5’-
monophosphothionate  
Rp-isomer (Rp-cAMPS) 
 
Competitive inhibitor 
of PKA, partial 
agonist for Epac1 176
OO
O
O
O
P
N
N
N
N
HO
NH2
Na + -
OO
O
O
S
P
N
N
N
N
HO
NH2
Na + -
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OO
O
O
O
P
N
N
N
N
HO
Na + -
H2N
O
Adenosine-3’,5’-
monophosphothionate  
Sp-isomer (Sp-cAMPS) 
 
Activates PKA,  
is not hydrolyzed by 
PDEs177 
8-(4-Chlorophenylthio)-
cAMP (8-pCPT-cAMP) 
 
Stimulates both PKA 
and GK178, inhibits 
PDE5179 
8-(4-Chlorophenylthio)- 
2’-O-methyl-cAMP  
(8-pCPT-2’-O-Me-cAMP) 
 
Epac-selective 
compound, does not 
activate PKA 34 
cGMP  
                        H 
 
 
 
 
 
Activates GKs, 
cGMP-regulated 
PDEs and cGMP-
gated channels 
(see 1.1.) 
N6-Monobutyryl-cAMP 
(6-MB-cAMP) 
 
 
Selective activator of 
A-site of PKA I 180 
OS
O
O
O
P
N
N
N
N
HO
NH2
Na + -
OO
O
O
O
P
N
N
N
N
HO
NH2
Na + -
S
Cl
OO
O
O
O
P
N
N
N
N
O
NH2
Na + -
S
Cl
CH3
OO
O
O
O
P
N
N
N
N
HO
Na + -
HN CH3
O
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N6-Mono-butylcarbamoyl- 
cAMP (6-MBC-cAMP) 
 
Specific activator of 
PKA type II with a 
strong preference for 
the A-site180 
8-Piperidinoadenosine-
3’,5’-cyclic 
monophosphorothioate, 
Sp-isomer 
(Sp-8-PIP-cAMPS) 
 
Site-selective 
activator of PKAII B-
site181 
8-Bromo-cAMP  
(8-Br-cAMP) 
 
Activator of PKA and 
Epac176,180 
OO
O
O
O
P
N
N
N
N
HO
Na + -
NHN
H
OCH3
H3CH3C
OS
O
O
O
P
N
N
N
N
HO
NH2
Na + -
N
OO
O
O
O
P
N
N
N
N
HO
NH2
Na + -
Br
 
To study the conformational changes induced by the compounds they were 
analyzed in vitro using the previously described sensor proteins purified from 
E.coli. The FRET-signals were detected directly after addition of compounds at 
different concentrations in a 96-well plate by using a high throughput MITRAS 
reader in order to obtain concentration-response dependencies for each 
substance. First, the ability of compounds to activate Epac1-camps was studied 
(Fig. 22, Table 3).  
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Fig. 22. Mapping of the Epac1 cAMP binding site using different compounds. A 
representative curve for each substance is shown (n=3). EC50-values are shown in 
Table 3. 
 
Interestingly, all compounds induced a conformational change to some extent in 
the binding domain of Epac1 but had different affinities. Two substances 
exhibited a partial effect. These were Rp-cAMPS and Sp-8-PIP-cAMP. The first 
substance is known as an inhibitor of PKA. The change of cyclic oxygen to 
sulfur with an additional change of overall configuration to Rp-isomer disfavors 
binding and activation of the CNBD. Previously, the action of Rp-cAMPS on 
Epac1 was analyzed by gel filtration experiments and revealed a lower affinity 
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than for cAMP, compatible with the present data. Rp-cAMPS was also 
demonstrated as a partial agonist in terms of Epac1 activation in intact cells176. 
Another, previously unidentified, partial agonist of Epac1 is Sp-8-PIP-cAMP 
(selective ligand for the B-site of PKA), which may have these properties due to 
the presence of the piperidine substitution in the 8-position of adenine. It is 
described that the purine ring of the cAMP molecule interacts with the binding 
domain of PKA, Epac and HCN by a series of hydrophobic interactions, which 
might be disturbed by introduction of polar substituents182. However, 
introduction of 4-chlorophenylthio substituent in the same position did not lead 
to partiality of activation, but significantly increased the affinities, almost 100-
fold for 8-pCPT-cAMP and 10-fold for the Epac selective substance 8-pCPT-2’-
O-Me-cAMP. A previous study176 has demonstrated various other substances to 
be full agonists for Epac; this was confirmed in the present work. All other 
substances studied were full agonists for Epac1-camps, although having 
different affinities. For example, cGMP had a lower affinity than cAMP or the 
sulphur-derivatives such as Sp-cAMPS were several times less affine. 
Surprisingly, 6-MB-cAMP, which was described not to activate Epac1, induced 
(like another 6-derivative 6-MBC-cAMP) a change of conformation in Epac1-
camps. The overall affinities exhibited by different substances on the Epac1 
binding domain were comparable with those estimated by an alternative method 
used for only Epac1 and PKA-sites before176, demonstrating that the current 
method applicable to study structure-effect relationships for CNBD. Thus, it 
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was, next, sought to analyze the behavior of previously non-characterized Epac2 
and HCN2 domains.    
 
 
Fig. 23. Mapping of the Epac2 cAMP binding site B using different compounds. A 
representative curve for each substance is presented (n=3). EC50-values are shown 
in Table 3. 
 
Fig. 23 demonstrates concentration-response dependencies of the substances to 
induce a conformational change in Epac2-camps. Here all compounds behave 
almost similar to the Epac1 situation with slightly different affinities. Rp-
cAMPS and Sp-8-PIP-cAMPS still act as partial agonist. However, the effect of 
97 
                                                       Results                      
Rp-cAMPS is significantly lower than on Epac1-camps. The Epac-selective 
activator 8-pCPT-2’-O-Me-cAMP also demonstrates a 10-fold lower affinity for 
Epac2 compared to Epac1 (Fig. 22). In general, the binding domains of Epac 
isoforms appear rather similar in their behavior towards different compounds. 
Next, it was sought to study a CNBD from another class of cAMP-regulated 
proteins. The most intriguing situation is observed when analyzing the 
conformational changes in HCN2-camps (Fig. 24, Table 3). Here, only cAMP 
remains a full agonist. cGMP and 6-MB-cAMP are only partial agonists 
stimulating the sensors rather weakly (~ 20 %). Sp-8-PIP-cAMPS is likewise a 
partial agonist as in the case of the Epac isoforms. Surprisingly, 8-Br-cAMP can 
also not completely activate the HCN2 CNBD, exhibiting only ~ 80% of the 
maximal signal. The sulphur substituents do not exhibit any measurable binding 
to the domain. Strikingly, 8-pCPT derivatives and 6-MBC-cAMP exhibit a 
increase in FRET upon activation, resulting in a signal in the other direction than 
antagonists (Fig. 24). The Epac-selective substance 8-pCPT-2-O’-Me-cAMP 
does not activate, but rather inhibits the conformational switch in HCN2-camps. 
Unlike Epac CNBDs, the binding site of HCN2-channel represents a structurally 
different domain. Only cAMP could fully activate HCN2-camps. This suggests 
the importance of all chemical components of cAMP, which interact with the 
binding site of the channel and induce a change of conformation. Further 
investigations are necessary to investigate the functional consequences of action 
of 8-pCPT-cAMP and 6-MBC-cAMP compounds, which might be proved to be 
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functional inhibitors of the channel, which plays a role in the physiological 
regulation of cardiac pacemaker activity22  
 
Fig. 24. Mapping of HCN2-camps using different compounds. Representative curves 
or solely data points for each substance are presented (n=3). EC50-values are shown 
in Table 3. 
 
The unusual behavior of the HCN2 binding domain in terms of the nucleotide-
induced conformational change could be explained based on the crystal structure 
of this protein22, which significantly differs from the domains of PKA and Epac2 
in terms of the chemical mechanisms of interaction with the cAMP molecule. 
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Fig. 25 schematically describes the major interactions between cAMP and 
phosphate-binding cassettes of PKA site B, Epac2 and HCN2. Interestingly, 
HCN2 domain has, compared to other cAMP binding sites, numerous residues 
hydrophobically interacting with the purine ring. Probably, this is a reason for a  
 
 
Fig. 25. Amino acid sequence alignment of phosphate binding cassettes of Epac2, 
PKA site B and HCN2 channel and the major chemical interactions with cAMP 
molecule. The highly conserved residues are in bold. The amino acids responsible for 
the hydrophobic interaction with the purine ring are shown in green. Compared to 
other proteins, HCN2 has numerous residues responsible for hydrophobic 
interactions with the adenine ring.  Hydroxyl bonds are presented as red lines22,182.  
 
major disturbance of the conformational change in the HCN2 domain for all 
compounds having substitutions in the adenine residue. 
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Table 3. EC50-values measured for different sensor proteins and cAMP analogues (in 
µM, means ± S.D., n=3). * - the substance exhibit an opposite effect on the 
conformational change in HCN2-camps. 
 
EC50-values for different proteins Substance  
Epac1-camps Epac2-camps HCN2-camps 
cAMP 2.53±0.34 1.0±0.2 9.1±2.1 
Rp-cAMPS 48.0±5.3 22.5±7.3 - 
Sp-cAMPS 4.8±0.5 1.3±0.2 - 
8-pCPT-cAMP 0.04±0.01 0.09±0.02 26.7±11.7* 
8-pCPT-2’-O-Me-cAMP 0.36±0.11 1.5±0.4 - 
cGMP 6.7±1.4 6.3±2.1 10.3±1.8 
6-MB-cAMP 1.2±0.1 0.63±0.14 1.9±0.8 
6-MBC-cAMP 0.33±0.13 0.11±0.04 9.5±0.3* 
Sp-8-PIP-cAMPS 55.2±6.3 7.5±2.0 3.0±1.6 
8-Br-cAMP 0.13±0.02 0.15±0.05 0.9±0.5 
 
In summary, the following conclusions can be drawn based on the comparative 
study of the conformational change induced by different compounds: 
 
1. Numerous cAMP derivatives that had been thought selectively activate 
PKA are capable of inducing a conformational change also in Epac1, 
Epac2 and HCN2.  
2.  Sp-8-PIP-cAMPS, a site-selective PKA activator with a preference for 
the B-site is a partial agonist for the binding domains of Epac2 and 
HCN2. 
3. Rp-cAMPS, an inhibitor of PKA, is a partial agonist for both Epac 
isoforms and has no major effect on HCN2. 
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4. A-site selective PKA-agonists, 6-MB-cAMP and 6-MBC-cAMP, are also 
full agonists for Epac1 and Epac2. 6-MB-cAMP is a partial agonist and 6-
MBC-cAMP is an inhibitor for HCN2.  
5. Epac selective substance 8-pCPT-2’-0-Me-cAMP does not activate 
HCN2.  
 
The described properties of different derivatives should be taken into account 
when doing biochemical experiments using them to specifically activate distinct 
signalling cascades. 
 
 
 
3.3   Development of cGMP biosensors 
 
The single-domain cAMP sensors proved to be very sensitive and efficient in 
various biological applications. They have allowed to overcome the major 
drawbacks of an older system based on the entire kinase as a backbone for a 
sensor. The same problems of low sensitivity, large unstable architecture and 
unphysiologically slow kinetics are the case for GK-based sensors for cGMP 
(see 1.4). Here, it was sought to improve real-time fluorescent measurements of 
cGMP signaling by developing similar single-domain biosensors, in order to 
increase the sensitivity and to achieve a physiological level of performance. 
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3.3.1  GK-based cGMP sensors  
 
Like in case of cAMP-binding proteins, GK has emerged to be not a unique 
binding partner of cGMP, which also binds to and activates PDEs and cGMP-
gated channels. All three effector proteins have one or two regulatory domains 
to bind cGMP (see 1.1). Although the activation mechanisms of these domains 
are poorly understood and no conformational change has been described so far, 
based on the similarities in structure to cAMP-domains it could be assumed that 
cGMP-binding sites of GK and regulatory GAF-domains of PDEs might have 
similar mechanisms of activation. Therefore, it was tested whether the 
generation of similar single-domain biosensors is possible with the high and low 
affinity domains of GKI (Fig. 26A). Indeed, fusing YFP and CFP to the low 
affinity B domain resulted in constructs exhibiting a dynamic change in FRET, a 
minor increase in a E242-A350 or a larger decrease in a L231-A350 construct 
(Fig. 26B,C). Although affinities of these sensors for cGMP were comparable 
with cAMP-indicators and the full-length GK-probes (~ 1µM and ~ 5µM, 
respectively), they demonstrated an extremely slow speed of activation after 
stimulating transiently transfected cells expressing these sensors with high 
concentrations of an NO-donor (see Fig. 28B). 
Fusing YFP and CFP to a single high affinity A domain of GKI (Fig. 26A) 
resulted in a sensor that demonstrated a decrease in FRET upon activation, 
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Fig. 26. Single-domain sensors based on GKI. A. Schematic representation of the 
constructs based on high affinity A and low affinity B domains of GKI. A relative 
change in FRET and EC50 values for cGMP are presented.  B and C. Fluorescent 
spectra of the sensor proteins based on the domain B of GKI taken as described in 
Fig. 7A from TsA201-cell lysates expressing two different constructs. Minor increase 
vs. decrease in FRET is shown. Representative spectra (n=4).  
 
which was also very slow in live cells (see Fig. 28B). Such slow kinetics of the 
activation could argue for a poor performance of these GKI-based sensors or for 
a general “slow nature” of this binding site. Unfortunately, the crystal structure 
of GK has not been solved, so that it seems difficult to make any predictions on 
or to further optimize the structure of the sensor. Thus, another cGMP effector 
was, next, chosen as a backbone, namely PDE2, for which the structure is 
available98. 
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3.3.2  Regulatory GAF-B domain of PDE2 as backbone for a 
cGMP-sensor 
 
In PDE2 cGMP-binding to the regulatory GAF-B domain induces the catalytic 
activity. The structural architecture of this domain resembles that of the 
previously discussed cAMP-binding domains. The fluorophores were inserted 
on the α-helices covering the phosphate-binding cassette (Fig. 27A,B). This led 
to a functional sensor protein exhibiting a large increase in FRET upon binding 
cGMP (Fig. 27B). Importantly, the speed of the FRET-signals was high and 
comparable with single-domain cAMP-sensors (see Fig. 28B), allowing the use 
of the PDE2-based indicator to measure cGMP with high temporal resolution. 
To study the selectivity of the sensor, its binding affinities were compared for 
cGMP and cAMP, obtaining 0.9±0.1 and 115±17 µM, respectively, which 
corresponds to a >120:1 preference for cGMP (Fig. 27C). The novel PDE2 
sensor exhibited slightly higher affinity and lower selectivity than the previously 
published cygnets sensors based on the GKI146. However, the speed of activation 
of GAF-B domain was faster compared to the single domains of GKI. 
To further investigate the ability of the sensor to report fast changes of cGMP in 
live cells, we stimulated such cells with atrial natriuretic peptide and the NO-
donor Na-nitroprusside (SNP). The PDE2-sensor was localized uniformly in the 
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cytosol of the cells and produced a rapid, reversible increase in FRET upon 
addition of ANP (Fig. 28A).  
 
 
 
Fig. 27. Development of cGMP sensors based on a single binding domain of 
phosphodiesterase. A. Structure of the constructs for PDE-based sensors, which 
were designed in a way similar to single-domain camps (see 3.1). B. Schematic view 
and fluorescent spectra of PDE2-based sensor measured as described in Fig. 7A. C. 
Representative saturation curves of PDE2 sensor for cGMP and cAMP (n=3) 
measured as in Fig. 12. EC50-values are stated in text. 
 
The increase in FRET was observed already within a few seconds after 
simulation, and was present in virtually every cell transfected with the PDE2-
sensor, demonstrating high robustness and temporal resolution of the single- 
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Fig. 28. Measurements of cGMP in live cells using PDE2 sensor. A. Sample YFP, 
CFP intensity and ratio traces of HEK293 cells transiently transfected with the ANP 
receptor NPRA and the PDE2-sensor after ANP stimulation with subsequent 
withdrawal of the agonist (n=5). A reversible increase of FRET is observed. B. 
Comparing kinetics of cGMP-signals after stimulation of endogenous soluble GC in 
HEK293 cells with 50 µM SNP as reported by PDE2, PDE5 (see 3.3.3 below), GKI A-
site (E111-E226) and B-site (L231-A350) sensors. Unphysiologically slow signals 
from GKI sensors are seen. Representative traces from at least 5 experiments.  
 
domain PDE2-based sensor. In contrast, the GK-based probes showed a much 
inferior performance that became especially visible by comparing the speed of 
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signals from PDE2 and GKI-based indicators after NO-donor stimulation (Fig. 
28B). A construct based on the high affinity A domain of GKI had a delay of 
98.5 ± 24.9 s (n=13) (Fig. 28B), typical also for cygnets146. Moreover, this 
protein had a diffuse cytosolic localization only in a minor percentage of the 
cells. The sensor based on the low affinity B domain of GKI produced not a 
delayed but also a very slow signal (Fig. 28B).  Therefore, the sensors based on 
the GKI seemed unsuitable for reliable measurements of intracellular cGMP. 
Their kinetic properties were significantly surpassed by creating a sensor based 
on a single GAF-B domain of PDE2.   
 
3.3.3 Improving the selectivity of cGMP measurements. 
Sensor based on the GAF-A domain of PDE5   
 
PDE2 is a dual-specific phosphodiesterase, which can be activated by higher 
cAMP concentrations (see 1.1 and Fig. 27C). To test whether the PDE2-sensor 
is switched on by cAMP in HEK293 cells, they were stimulated with saturating 
amounts of the β-adrenergic agonist isoproterenol, increasing cAMP 
concentrations in this cell type to higher µM values. Under these conditions, a 
minor signal was observed (Fig. 29A, top), demonstrating that the selectivity of 
the PDE2-sensor is not high enough and might lead to contamination of cGMP-
FRET by cAMP in some applications.  
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Fig. 29. PDE5-based sensor demonstrates high selectivity for cGMP. A. 
Measurements with PDE2 (E392-A525)- and PDE5 (E154-A308)-based sensors 
upon full stimulation of cGMP- and cAMP-production in cells as described in Fig. 
28A. PDE2-sensor shows a small signal to isoproterenol (Iso), whereas the PDE5-
based sensor gives no apparent response to Iso (representative from n=4 cells). B. 
High selectivity of the PDE5-sensor was confirmed also by concentration-response 
curves measured in lysates of transiently transfected TsA201 cells as in Fig. 12. 
EC50-values were 1.5±0.2 µM for cGMP and 630±100 µM for cAMP (n=3). C. 
Characterization of chemical selectivity of PDE5- and GK-B (L231-A350)-sensors 
using 8-Br-cGMP and 8-pCPT-cGMP (both 100 µM) in HEK293 cells transiently 
transfected with PDE5- or GKI (L231-A350)-constructs. Representative traces (n=5). 
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To increase the selectivity for cGMP, the GAF-A binding domain of PDE5A1 
was used, which is described as a cGMP-specific phosphodiesterase with a high 
selectivity for cGMP 99. The position of fluorophore attachment was optimized 
based on the PDE2-sensor design and using the model structure of PDE5 GAF-
A domain183. Several constructions were produced to obtain a sensor with an 
amplitude of the FRET signal similar to PDE2-probe (Fig. 27A). The PDE5-
sensor demonstrated no apparent signal after cAMP pathway stimulation and 
almost similar kinetic properties as the PDE2-indicator (Fig. 29A, bottom). 
Indeed, the selectivity for cGMP was greatly improved as measured in vitro, 
exceeding 400:1 preference for cGMP, whereas cAMP in micromolar 
concentrations was not able to fully stimulate the sensor (Fig. 29B).  
The next series of experiments aimed at a characterization of chemical 
selectivity of PDE- and GK-based sensors using cGMP analogs. 8-Br-cGMP, 
which is known as an agonist for GKI and PDEs184, was also able to activate the 
PDE5-sensor (Fig. 29C) and PDE2 sensor (not shown). However, 8-pCPT-
cGMP, which was described not to activate PDEs184, did not produce any signal 
of the PDE5-sensor. In contrast, a single-domain GKI-sensor was activated by 
this analog (Fig. 29C), demonstrating that the sensors based on single cGMP-
binding domains retain the biochemical properties of the unmodified binding 
sites and can differentiate between derivatives stimulating distinct cGMP-
dependent signaling pathways.   
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In summary, novel cGMP sensors based on single GAF domains of PDE2 and 5 
were created to achieve highly sensitive dynamic cGMP measurements with 
higher temporal resolution than have been described previously for kinase-based 
cygnets. Comparable to cAMP sensors, single-domain cGMP probes greatly 
improved cyclic nucleotide measurements in live cells, opening up new 
possibilities for physiological studies. 
 
 
 
 
3.4   Applications of cGMP sensors 
 
3.4.1  Spatio-temporal dynamics of cGMP production by 
soluble and membrane-bound guanylyl cyclases   
 
Membrane-bound GC as an intracellular domain of the ANP receptor NPRA and 
soluble NO-activated GC represent two distinct types of enzymes, which exhibit 
different properties (see 1.1). For example, in cardiac myocytes different effects 
of CNP and SNP on contractility were observed that led to the hypothesis that 
NRPA-receptor signals are compartmentalized185. To analyze the spatio-
temporal aspects of these two different signalling cascades, the kinetics of ANP 
and the NO-donor SNP signals were compared in HEK293 cells. 
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Interestingly, the speed of cGMP production after ANP stimulation was higher 
than after the addition of the NO-donor (Fig. 30). This behaviour of different 
GC types could be explained by the site of their intracellular localization. 
Membrane-bound GC is readily activated by ANP, which binds to the 
extracellular domain of the NPRA-receptor and through a conformational 
change activates the GC activity in the intracellular domain (see 1.1). Soluble 
GC, however, is activated by NO which applied extracellulary must first diffuse 
through the plasma membrane and into the cytosol of the cell to induce cGMP 
synthesis.  
 
 
Fig. 30. Comparing kinetics of cGMP signals after stimulation of different GC types. 
HEK293 cells were transiently transfected with PDE2-sensor and NPRA receptor. 
Addition of ANP leads to a rapid increase of intracellular cGMP, whereas activation of 
endogenous soluble GC with SNP results in a slower cGMP accumulation in cells. 
Representative experiments from n=6 cells for each condition.  
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The differences in kinetics of cGMP production by different types of GC might 
be important for the functional compartmentation of cGMP action, providing 
higher concentrations of rapidly synthesized cGMP at the plasma membrane. In 
the HEK293 cells studied here, microscopic imaging showed no visible 
restriction of cGMP diffusion (not shown). After both ANP and SNP stimulation 
the whole cell altered its FRET, suggesting that the entire cytosol was filled with 
cGMP without apparent restricted domains. In general, similar diffusion patterns 
were monitored as for free cAMP-diffusion. To further analyze possibilities of 
compartmentation, more physiologically relevant cell types were used.  
 
3.4.2  Characterization of cGMP signaling in mesangial cells 
 
Having demonstrated high performance of the PDE5-sensor in HEK293 cells it 
was, next, studied how the sensor reports cGMP-dynamics in a physiologically 
relevant system. Mesangial cells of kidney glomerula represent a specialized 
type of smooth muscle cells, which regulates blood vessel tension in response to 
angiotensin as a vasoconstrictor and to ANP, NO, and cAMP-stimulating 
hormones, which induce vasodilatation158. Primary rat mesangial cells were 
isolated and transfected with PDE5-sensor without any additional manipulation 
to maintain physiological conditions for cGMP-production. Both ANP and SNP 
induced a rapid increase in FRET which is measurable already within 5 seconds 
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after stimulation (Fig. 31A), demonstrating high sensitivity and temporal 
resolution of the sensor.  
Interestingly, in mesangial cells the FRET signals measured by PDE5-sensor 
were even bigger than in HEK293 cells (compare Figs. 28,29,31A), reaching up 
to 45 % ratio change after ANP and 55 % after SNP stimulation. The FRET- 
signals were fully reversible and did not demonstrate a long plateau at saturating 
concentrations of ANP and SNP (Fig. 31A), suggesting that the sensor has a 
large dynamic range to measure cGMP at physiologically relevant 
concentrations.  
In contrast to HEK293 cells transfected with NPRA receptor (Fig. 30), SNP-
induced cGMP signals in mesangial cells were faster than ANP signals (Fig. 
31A), which might be due to a lower expression of endogenous ANP-receptors 
on these cells compared to the higher amounts of soluble GC. Full stimulation of 
cAMP production by isoproterenol produced a very small increase in FRET, 
which was negligible compared to cGMP-induced changes in PDE5-sensor 
ratio. It suggests a very high cAMP production induced by Iso in these cells 
which results in a minor activation of the PDE5-sensor (Fig. 31A).  
Rapid functional effects of cGMP (and of cAMP, for comparison) in mesangial 
cells were also confirmed by analysis of the phosphorylation of the GK- and 
PKA-substrate protein, vasodilator-stimulated phosphoprotein (VASP). 
Isoproterenol (via PKA) and SNP or ANP (via GK) all cause phosphorylation of 
VASP as evidenced by a shift in electrophoretic mobility and by detection with 
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Fig. 31. Measuring cGMP-dynamics in primary rat mesangial cells. A. Monitoring 
reversible increases in cGMP after ANP and NO-donor stimulation in rat mesangial 
cells transiently transfected with the PDE5 (E154-A308)-sensor. Representative 
experiments (n=5) for each compound are shown. FRET-dynamics are presented as 
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a YFP/CFP ratio change in percent. Red arrow indicates the time-point of agonist 
application. B. Western blot analysis of GK substrate phosphorylation after incubating 
mesangial cells for 5 minutes with 10 µM Iso, 10 µM SNP or 5 nM ANP. The lower 
band of P-VASP represents the cGMP-mediated phosphorylation by GK, the upper 
band the PKA-induced phosphorylation. C. Time-dependent VASP-phosphorylation 
analyzed by Western blot after stimulation of mesangial cells with 50 µM SNP. 
Apparently already after 30 s GK phosphorylates its substrate. D. Cell imaging of 
intracellular cGMP in mesangial cells stimulated by ANP or SNP and visualized in 
real time by increases in FRET (YFP/CFP ratio) of the PDE5 sensor. Representative 
ratiometric images at different times after stimulation are presented (n=5).   
 
phosphorylation-sensitive antibodies (Fig. 31B). Interestingly, GK-dependent 
VASP phosphorylation is visible already within 30 s after stimulation of cGMP 
production with SNP (Fig. 31C). Maximal phosphorylation was achieved after 2 
minutes, demonstrating a correlation of phosphorylation kinetics (Fig. 31C) with 
cGMP-levels as measured with the PDE5-sensor (Fig. 31A).  
Finally, imaging experiments in live mesangial cells were done for spatially and 
temporally resolved monitoring of cGMP-production (Fig. 31D). Already 25 s 
after application of ANP or SNP a visible change in cGMP was observed. In 
contrast, previously developed indicators did not allow to image cGMP 
elevations in a closely related cells type up to 200 s after activation146. The large 
increase of cGMP of mesangial cells reported by the PDE5-sensor was 
uniformly distributed in the cytosol without any evidence for compartmentation 
(Fig 31D).  
In summary, using primary mesangial cells stimulated with ANP and SNP as a 
physiological model, it was demonstrated that the PDE5-sensor has high 
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sensitivity and a large dynamic range. It reports rapid changes in intracellular 
cGMP and demonstrates high amplitude (up to 55% dynamic change) of the 
FRET-signal, which allows to use the sensor for live cell imaging in order to 
study cGMP signalling with high spatial and temporal resolution.   
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4    Discussion 
 
The present study aimed at developing effective methods for physiologically 
relevant imaging of cyclic nucleotide signaling in live cells. Classical 
biochemical techniques have unraveled the major elements and mechanisms of 
the intracellular signaling involving cAMP and cGMP. However, it remained 
unclear how the second messengers exert their effects in a living system, such as 
single cells of an organism, in terms of spatial and temporal regulation. The 
major question of the second messenger paradigm is how only two types of 
cyclic nucleotides can achieve high specificity and coordinated regulation of 
hundreds of proteins and intracellular functions. A hypothesis proposed in recent 
years suggests the compartmentation of signaling, which results in localized 
effects of cyclic nucleotides not equally distributed in cells via restriction of 
their diffusion by phosphodiesterase activity. The most commonly accepted 
explanation for local signaling events is that cyclic nucleotides can not freely 
diffuse on long distances from activated receptors, which are surrounded by 
PDEs that restrict cAMP- or cGMP-diffusion124,186-188. The detailed mechanisms 
of compartmentation, however, remain largely elusive. In the present work, new 
highly sensitive biosensors were developed to image cAMP- and cGMP-
signaling in live cells and were applied to different physiologically relevant 
questions, including the characterization of phosphodiesterase activity as an 
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enzyme responsible for compartmentation. Another issue of the work was to 
delineate the mechanisms of interaction of cAMP and cGMP cascades at the 
level of phosphodiesterases. Moreover, using the sensors based on native 
binding domains of cAMP- and cGMP-regulated proteins, chemical and 
structural mechanisms of CNBD activation and specificity were addressed. 
Finally, clinically relevant methods of cAMP-detection were developed to 
screen for receptor autoantibodies as a cause of heart failure.      
 
 
4.1    Family of single-domain biosensors for cyclic nucleotides 
 
FRET-imaging has become a revolutionary approach to monitor biochemical 
signaling events in living systems. Based on GFP and its mutants various 
biosensors have been developed that allowed to visualize protein-protein 
interactions and conformational changes, thereby measuring receptor activation, 
G-protein dissociation, protein phosphorylation, intracellular dynamics of 
seconds messengers etc. The first biosensors for cAMP and cGMP were 
developed based on large molecules of protein kinases fused to GFP-mutants to 
monitor FRET, which was supposed to reflect changes in second messenger 
concentrations123,142,146. However, such sensors had limited performance and 
potential, which were the result of biochemical properties of these kinases.  
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PKA is a tetrameric holoenzyme comprised of regulatory and catalytic subunits 
which dissociate after binding of cAMP. The ligand binds to four different sites 
of the complex with different affinities, triggering a complex mechanism of 
enzyme activation occurring through a series of conformational changes that 
lead to release of catalytic subunits23,24,153. This particular later event, the 
dissociation of the complex, is monitored by using older fluorescent cAMP 
biosensors. The complex nature of this process results in an apparent delay of 
cyclic nucleotides signals. Moreover, the catalytic activity of the enzyme is 
directly involved in regulation of cAMP-levels via phosphorylation and, 
thereby, activation of PDE4. This is detrimental for reliable measurements. 
Furthermore, the whole PKA complex has an interaction interface with 
anchoring proteins, that target it to cell membranes and prevent unrestricted 
cAMP measurements in the cytosol. To overcome these various disadvantages a 
new approach was developed in this study, which for the first time was based on 
a single CNBD as a backbone for a fluorescent sensor to measure cAMP. The 
novel sensors took advantage of the prediction that cAMP induces a 
conformational change in the binding domain152. Based on the crystal structure 
of Epac2 a new sensor, Epac2-camps, was developed, which rapidly reported 
dynamic changes in intracellular cAMP upon receptor activation. The sensor 
had only one single cAMP-binding site, was deplete of catalytic and interacting 
domains and contained both fluorophores on one protein molecule allowing for 
easily detectable intramolecular FRET, which dynamically changed, in response 
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to cAMP-concentrations. The very first in vitro and live cell experiments 
demonstrated how much faster the cAMP-signals were detected by Epac2-
camps compared to a previously published PKA-sensor. These data showed the 
poor performance of the kinase-based indicator, which due to sequential 
cooperative ligand binding and catalytic activity is not able to rapidly report 
changing cAMP-concentrations in cells. Single-domain Epac2-camps opened up 
new ways for cAMP-imaging. Based on the same principle, similar cAMP 
sensors were, next, developed using all cAMP-binding domains described up to 
date. From the Epac1-domain the Epac1-camps sensor was generated, which 
demonstrated the largest amplitude of the signal. A single binding domain of the 
HCN2-channel became part of HCN2-camps, which exhibited lower affinity for 
cAMP, allowing to extend the dynamic range of the sensors towards higher 
cAMP-concentrations. PKA domains B and A served as backbones for PKA-
camps and the A-domain sensor, respectively. The latter was able to visualize 
not only cAMP-binding but also the interaction with the catalytic subunit. Later 
on, the crystal structure of this domain in complex with the catalytic subunit was 
solved and indeed proved a conformational change in the A domain as a 
mechanism of catalytic subunit release24. 
The developed single-chain cAMP-sensors proved useful in several applications. 
First, the spatio-temporal dynamics of cAMP were analyzed in different cell 
types (simple HEK293 cells, expressing various receptors, and hippocampal 
neurons) after stimulating cAMP-synthesis via different GPCRs. cAMP freely 
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diffused in the cytosol from the patch of activated receptors through the whole 
cell within a few hundred milliseconds without visible barriers. It was possible 
to calculate the speed of this diffusion and its coefficient, indicating a free 
unrestricted diffusion of cAMP (see 3.2.1). To better understand how 
compartmentation could be provided under this free cAMP diffusion, the 
activity of the major compartmentalizing enzymes, PDEs, was directly 
monitored in live adrenal cells on the basis of cAMP-hydrolysis. Interestingly, 
the kinetics of PDE2 action in these cells was enormously fast. Not only did 
PDE2 rapidly hydrolyze cAMP, but the speed of cAMP-degradation is even 
faster than the speed of cAMP synthesis in the continuing presence of forskolin, 
ACTH or adrenergic receptor agonist (see 3.2.2). Such properties of PDE 
characterize this enzyme as a very fast regulator of cAMP-concentrations in 
cells. Its high activity makes it capable of compartmentalizing cAMP-signaling. 
Why, then is there no evidence of cAMP-compartmentation in our cells? 
Constitutively active PDEs were described to be localized together with cAMP-
targets such as PKA through interaction with AKAPs145. This colocalization of 
cAMP-targets with PDEs might just locally restrict the access of cAMP to PKA, 
Epac or channels, preventing their activation. In this case one would see free 
cAMP gradients propagating in the whole cell, which do not activate particular 
proteins in microdomains with a high PDE activity which are too small to be 
localized by light microscopy. This scenario might be the reason for the 
apparent unrestricted cAMP diffusion observed with Epac1-camps (see 3.2.1). 
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Only those sensors, which are themselves targeted to particular subcellular 
locations in close proximity with PDEs (PKA sensor or olfactory cyclic-
nucleotide-gated channels used to measure cAMP), would then report 
compartmentation124,186,188-190 because they are located inside such 
microdomains, protected from cAMP by PDEs, which create a kind of shelter 
zones or barriers for cyclic nucleotides coming from the outside where they 
diffuse freely. Such barriers would not allow the targets to be activated, even 
thought the second messenger is present around in the cytosol. This hypothesis 
might also explain a visible absence of barriers for cGMP (see 3.4.2). Another 
possibility would be that the cells used in the present study have no cAMP-
compartments, which might be the case for highly specialized types of cells such 
as cardiomyocytes. 
To image cGMP, novel sensors were developed based on single regulatory GAF 
domains of PDE2 and 5 (see 3.3). Similar to cAMP-sensors, single cGMP-
binding domains yielded sensors which were, for the first time, able to report 
dynamic changes of cGMP on the physiologically relevant timescale. An older 
approach using a kinase-based indicator146 was temporally limited: it produced 
extensive delays in its responses, whereas in reality during this time several 
cellular proteins such as GK (Fig. 30C), PDEs or channels are already activated. 
By creating single-domain probes in the present study it was demonstrated that 
the binding sites of GK fused to CFP and YFP, however, exhibit very slow 
kinetics and, therefore, could not be used to report rapidly changing cGMP-
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concentrations. GAF-domains, on the contrary, produced sensors capable of 
measuring cGMP with high temporal resolution. Due to its physiological 
properties98 the binding domain of PDE2 was not selective enough for cGMP, 
which led to a minor contamination of the FRET-signal in the presence of high 
concentrations of cAMP. To produce sensors of even higher selectivity, a single 
GAF-A domain of cGMP-specific PDE5 was, next, successfully used to create a 
highly selective cGMP sensor.  
Having new cGMP imaging tools developed it was then attempted to 
characterize cGMP-compartmentation. Similar to the cAMP system, no visible 
restrictions for cGMP diffusion were observed after stimulation of both 
membrane-bound and soluble GC. In simple HEK293 cells as well as in more 
physiologically relevant mesangial cells, cGMP freely diffused in the cytosol 
and did not demonstrate any visible compartmentation, supporting the idea that 
compartmentation of the signaling by both cyclic nucleotide might be organized 
rather at the level of second messenger access to the effectors, than by restriction 
of their whole-cell diffusion. Another possibility could be the absence of the 
microdomains in this particular cell type. 
The single-domain cyclic nucleotide sensors designed, developed and applied in 
the present study have allowed to overcome the major disadvantages typical for 
old generation of kinase-based indicators for cAMP and cGMP, which 
prevented them to be widely applied for live cell imaging (see 1.4): 
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1. The novel biosensors are single relatively small proteins which consist of a 
CNBD flanked with two GFP mutants. Thus, they can by easily transfected into 
mammalian cells and exhibit good expression levels. They can also be expressed 
in and purified from bacteria in fully functional state. The latter aspects might be 
important for large scale and low-expenditure purifications in order to measure 
cAMP or cGMP for drug development purposes (further discused in 4.3). 
2. The single-domain biosensors lack the catalytic activity characteristic for 
PKA and GK, thereby excluding the possibility of interfering with biochemical 
processes in cells such as activation of negative “feed-back” mechanisms or 
phosphorylation of other proteins. 
3. Biosensors developed in the present study (in contrast to PKA and GK) lack 
interacting domains which might anchor them to different subcellular locations, 
allowing to measure uniformly cytosolic cyclic nucleotide signals. 
4. Single CNBD as a backbone for a sensor allows, for the first time, to measure 
true kinetics of cAMP and cGMP, maximally corresponding to physiological 
fluctuations of the second messengers in cells. This is achieved due to depletion 
of CNBD cooperativity and sequential binding of cAMP or cGMP to multiple 
sites in PKA and GK. 
The development of single-domain biosensors for cyclic nucleotides became 
possible as a result of our understanding of the mechanisms of CNBD-
activation, where the central role is played by the ligand-induced conformational 
change.   
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4.2    Conformational change as a ubiquitous activation 
mechanism of cAMP- and cGMP-regulated proteins 
 
At the beginning of the cAMP-sensor development there were only a few 
indirect and rather intuitive evidences available that suggested a conformational 
change as a mechanism for CNBD-activation (see 1.5). It was mainly the work 
done by Holger Rehmann and Alfred Wittinghofer which presented at that time 
the first apo-structure of a CNBD of Epac2 152. Comparing this structure with 
the crystallographic data for binding domains of PKA in the presence of cAMP25 
the authors made a prediction that during CNBD activation a major 
conformational rearrangement should take place in the C-terminal helical part of 
the domain leading to release of the autoinhibited catalytic site of the protein152. 
A similar mechanism has been postulated for activation of GK by cGMP even 
though its crystal structure is unavailable69. 
Based on this proposed mechanism we started to construct cAMP-biosensors, 
which should monitor the conformational change in the high-affinity binding 
domain of Epac2 and thereby report changing cAMP-concentrations by means 
of FRET. In this study, FRET could be considered not only as a tool for 
molecular imaging and development of biosensors (see 1.2), but also as a 
method that allows to monitor conformational changes in protein molecules. 
Epac2-camps exhibited a conformational change dependent on cAMP-
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concentrations, thereby proving the hypothesis of a conformational 
rearrangement as a mechanism of activation.   
The next question that the study tried to address was whether the conformational 
change observed for Epac2 could be the case for other cAMP-binding proteins, 
representing a kind of ubiquitous mechanism of activation. Indeed, the 
development of Epac1-camps, HCN2-camps and the sensors based on single A 
and B domains of PKA confirmed a uniform universal mechanism of cAMP-
induced sensor activation, which supports a common principle of regulation.  
However, the fine mechanisms of the activation of different domains were 
distinct and dictated by their individual structure. This could be appreciated in 
chemical mapping experiments where different cAMP-derivatives were used to 
characterize conformational changes in CNBDs of Epac1, Epac2 and HCN2 (see 
3.2.3). These experiments provided two important observations. First, the 
chemical selectivity of Epac1-camps determined by FRET was nearly identical 
to the native CNBD measured previously using biochemical techniques176, 
nicely illustrating that positioning of GFP mutants on the CNBD did not alter 
the selectivity of the domain and did not disfavor its physiological binding and 
activation properties, allowing further domains (of Epac2 and HCN2) to be 
characterized in a similar way. Secondly, different substances behaved 
differently on the domains of Epacs and HCN2, again demonstrating distinct 
structure-dependent mechanisms of cAMP-binding. Several substances were 
identified that activated the HCN2-domain only partially or even induced a 
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conformational change opposite to that driven by cAMP. Further investigations 
might be needed to study how these compounds might affect the activity of the 
whole channel. 
After the single-domain cAMP-sensors were developed and described191, 
excellent crystallographic investigations performed in the group of Susan Taylor 
were presented, where the crystal structure of the same CNBD of PKA was 
solved in the absence and presence of the ligand, now unequivocally confirming 
the ligand-induced conformational change as a mechanism of PKA-activation. 
The first study demonstrated this mechanism for the B domain of PKA 
regulatory subunit153. The second investigation deal with the mechanism of 
activation of the A domain of PKA in the context of catalytic subunit release 
(see 1.5) 24. Crystallographic data presented in this publication were in full 
agreement with the functional behavior of the sensor based on the A-site of PKA 
with respect to cAMP-binding and catalytic subunit release (see 3.1.2), 
indicating the similar scenario of cAMP-induced PKA complex activation (see 
1.4). 
Much less is known for cGMP-binding domains and their activation. Except for 
the crystal structure of cGMP-bound GAF-domains of PDE2 solved in Joseph 
Beavo’s laboratory98 and some other studies indirectly demonstrating 
conformational rearrangements in GK (discussed in 1.5) there was no further 
evidences which might characterize molecular mechanism of cGMP-domain 
activation. In the present work, several biosensors were developed based on a 
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conformational change of single binding domains of GK, PDE2 and PDE5 (see 
3.3.). By creating these sensors, it was, for the first time, demonstrated that a 
cGMP-induced conformational change is present and might play a role in the 
activation of regulatory GAF domains of PDE2 and 5. Therefore, a cyclic 
nucleotide-induced conformational change seems to represent a central 
mechanism of CNBD activation for both cAMP and cGMP binding domains.                   
 
4.3    Clinically relevant applications of the cAMP and cGMP 
sensors  
 
How can the sensors developed in this study be applied for purposes of 
contemporary pharmacy and medicine? As was mentioned in part 1.1, cAMP 
and cGMP as second messengers play pivotal roles in numerous physiological 
and pathological processes. cAMP-synthesis in cells is regulated by GPCRs, 
which represent the target of about one third of currently used drugs. The 
cGMP-system becomes constantly more attractive for therapeutic intervention, 
for example because hormones like ANP stimulate cGMP-synthesis which is 
beneficial for heart failure. Here, some possibilities will be considered how the 
single-domain cAMP- and cGMP-sensors could be applied for disease 
diagnostics and drug discovery. 
One intriguing example of a disease where cAMP produced by adrenergic 
receptors plays a causative role in pathogenesis is autoimmune dilated 
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cardiomyopathy. This disease is often characterized by the production of 
activating antibodies against β1-AR, which induce elevated cAMP production in 
cardiac myocytes leading to enhanced contractility and over extensive periods of 
time to development of heart failure. In the present study a diagnostic system 
has been established that allows to measure autoantibodies against β1-AR in 
preparations from blood serum of DCM patients (see 3.2.3). A highly sensitive 
cAMP-sensor Epac1-camps transiently transfected in cells expressing β1-AR 
served as an indicator for antibodies stimulating the receptor. The new system 
allows for reliable functional measurements and identification of autoantibodies 
in their ability to increase cAMP-levels in live cells. Compared to classical 
techniques such as ELISA or cAMP-RIA, the FRET-based approach 
demonstrates much higher sensitivity and reliability. It allows to detect 
antibodies in much greater number (up to 80 %) of patients with clinical 
symptoms of DCM. The cAMP-signals induced by autoantibodies could be 
largely blocked by β1-AR antagonists, although not fully. Thus, the system is 
capable of analyzing efficacy of different therapeutic approaches for this disease 
and might be used in the near future for screening of new strategies and 
compounds to antagonize the detrimental effects of antibodies.  
In principle, the biosensors developed here for cAMP and cGMP might be 
applied for screening of any potential therapeutically interesting compound that 
affects mechanisms of cAMP- and cGMP-synthesis and degradation. Beta-
blockers are not the only examples of medicines which regulate cAMP-synthesis 
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via modulation of GPCR activity. Several further receptors are coupled to 
regulation of cAMP synthesis via Gs or Gi proteins such as serotonin and 
adenosine receptors used as targets for anti-inflammatory and anti-allergic drug 
or α-adrenergic receptors conveying blood pressure lowering effects of clonidine 
or modulation of blood vessel tone by oxymetazoline. For the development of 
new therapeutics acting at GPCRs, which are linked to cAMP-production, it is 
important to have reliable high-throughput systems for cAMP-measurements. 
Classical methods such as RIA are time-consuming and relatively expensive. 
They include the use of radioactivity and do not allow to measure cAMP with 
high temporal resolution. Fluorescent biosensors developed in this study, on the 
other hand, are capable of highly sensitive cAMP measurements with low cost, 
high sensitivity, temporal and spatial resolution. The goal of the near future 
would be to establish the technique in a high-throughput format on a microtiter 
plate, which perfectly works with purified sensor proteins but has not been 
developed so far for cell-based assays. This would allow to perform a fast 
screening of compounds which affect cAMP and to diagnostically test for anti-
β1-AR autoantibodies in large collectives of patients.  
Strategies aimed at regulation of cGMP concentrations in cells have been 
gaining increased interest over the last years192. Natriuretic peptide hormones are 
used in medicine to increase cGMP in cardiac myocytes in order to counteract 
detrimental pathological mechanisms of heart failure and remodelling after 
cardiac infarction193. In addition to their cardioprotective properties natriuretic 
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peptides could also be applied as vasoprotective drugs194. The action of peptide 
hormones or other therapeutically promising compounds on cGMP-production 
in live cells could be monitored used the cGMP-biosensors developed in the 
present study (see 3.3).  
Another interesting aspect of therapy is the use of drugs that regulate cAMP- 
and cGMP-hydrolysis by inhibiting different PDE isoforms. The most 
therapeutically relevant ones are PDE4 and PDE5. PDE4 inhibitors have been 
developed and are being successfully applied for the treatment of bronchial 
asthma, inflammatory and allergic diseases195 or as antidepressants196. However, 
two very effective PDE4 inhibitors, rolipram and roflumilast, have been recently 
withdrawn from the marked due to their side effects. Now, novel PDE4 
inhibitors should be developed, which dictates a need for sensitive screening 
techniques.  In the present study, the activity of PDE2 was, for the first time, 
monitored in real time using a physiologically relevant cell system including its 
modulation by a selective inhibitor197 (see 3.2.2). Epac-based cAMP-biosensors 
used to report PDE-induced cAMP-hydrolysis could be applied for screening of 
compounds acting at other PDE isoforms such as PDE4, thereby providing a 
measuring system for PDE4 inhibitors.  
cGMP-dependent PDEs such as PDE5 represent another important target of 
therapeutics, for example sildenafil currently used to treat erectile dysfunction. 
The activity of PDE5 inhibitors might be also measured in real time in live cells 
using PDE-based cGMP-sensors developed in this study (see 3.3 and 3.4).         
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In summary, novel single-domain fluorescent biosensors for cAMP and cGMP 
could be effectively applied for the diagnostics of DCM-antibodies as well as for 
drug development, including high-throughput screening of therapeutically 
promising compounds that regulate cAMP- and cGMP-production (agonists and 
antagonists of GPCR and GCs) and hydrolysis (PDE inhibitors).      
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Summary 
 
The cyclic nucleotides cAMP and cGMP are two ubiquitous important second 
messengers, which regulate diverse physiological responses from vision and 
memory to blood pressure and thrombus formation. They act in cells via cAMP- 
and cGMP-dependent protein kinases (PKA and GK), cyclic nucleotide-gated 
channels and Epac. Although the concept of cyclic nucleotide signalling is well 
developed based on classical biochemical studies, these techniques have not 
allowed to analyze cAMP and cGMP in live cells with high temporal and spatial 
resolution.  
In the present study fluorescence resonance energy transfer was used to develop 
a technique for visualization of cAMP and cGMP in live cells and in vitro by 
means of fluorescent biosensors. Ligand-induced conformational change in a 
single nucleotide-binding domain flanked with green fluorescent protein mutants 
was used for dynamic, highly sensitive measurements of cAMP and cGMP. 
Such biosensors retained binding properties and chemical specificity of 
unmodified domains, allowing to image cyclic nucleotides in a physiologically 
relevant range of concentrations. To develop cAMP-sensors, binding domains of 
PKA, Epac and cAMP-gated HCN-channel were used. cGMP-sensors were 
based on single domains of GK and phosphodiesterases (PDEs)   
Sensors based on Epac were used to analyze spatio-temporal dynamics of cAMP 
in neurons and macrophages, demonstrating that cAMP-gradients travel with a 
high speed (~ 40 µm/s) throughout the entire cytosol. To understand the 
mechanisms of cAMP-compartmentation, kinetics properties of phosphodi-
esterase (PDE2) were, next, analyzed in aldosterone producing cells. PDE2 is 
able to rapidly hydrolyze extensive amounts of cAMP, so that the speed of 
cAMP-hydrolysis is much faster than that of its synthesis, which might serve as 
a basis of compartmentation. cAMP-sensors were also used to develop a 
clinically relevant diagnostic method for reliable detection of β1-adrenergic 
receptor autoantibodies in cardiac myopathy patients, which has allowed to 
significantly increase the sensitivity of previously developed diagnostic 
approaches.  
Conformational change in a single binding domain of GK and PDE was, next, 
used to create novel fluorescent biosensors for cGMP. These sensors 
demonstrated high spatio-temporal resolution and were applied to analyze rapid 
dynamics of cGMP production by soluble and particulate guanylyl cyclases as 
well as to image cGMP in mesangial cells. 
In summary, highly sensitive biosensors for cAMP and cGMP based on single 
cyclic nucleotide-binding domains have been developed and used in various 
biological and clinically relevant applications. 
 
 
 Zusammenfassung 
 
Die zyklischen Nukleotide cAMP and cGMP sind zwei ubiquitäre Botenstoffe, 
die verschiedene physiologische Prozesse regulieren, vom Sehen und 
Gedächtnis bis zu Blutdruck und Thrombusbildung. Sie wirken über cAMP- und 
cGMP-abhängige Kinasen (PKA und GK), Kanäle und Epac. Obgleich die 
Funktionen von zyklischen Nukleotiden in klassischen biochemischen Studien 
gut untersucht sind, ermöglichen diese Methoden nicht, cAMP und cGMP in 
lebenden Zellen mit hoher zeitlicher und räumlicher Auflösung zu analysieren.  
In dieser Arbeit wurde Fluoreszenzresonanzenergietransfer benutzt, um eine 
Technik für die Visualisierung von cAMP and cGMP in lebenden Zellen und in 
vitro zu entwickeln. Ligand-induzierte Konformationsänderung in einer 
einzelnen, mit Grünfluoreszenzproteinmutanten fusionierten Bindungsdomäne 
diente als Grundlage für Biosensoren, die dynamische, hochsensitive Messungen 
von cAMP und cGMP ermöglichen. Bei solchen Sensoren wurden die 
chemischen und Bindungseigenschaften von unmodifizierten Domänen 
aufrechterhalten, was die cAMP- und cGMP-Messungen im physiologischen 
Konzentrationsbereich  in lebenden Zellen ermöglicht. Für die Entwicklung der 
cAMP-Sensoren wurden die Domänen von PKA, Epac und von einem cAMP- 
gesteuerten HCN-Kanal benutzt. cGMP-Sensoren beruhen sich auf den 
Bindungsdomänen von GK und Phosphodiesterasen (PDEs).     
Mit Hilfe der auf Epac-basierten Sensoren wurde die cAMP-Dynamik in 
Neuronen und Makrophagen zeitlich und räumlich aufgelöst. In diesen Zellen 
diffundiert cAMP mit hoher Geschwindigkeit (~ 40 µm/s) frei durch das ganze 
Zytosol. Um die Mechanismen der cAMP-Kompartimentierung besser zu 
verstehen, wurden die kinetischen Eigenschaften der PDE2 in 
aldosteronproduzierenden Zellen analysiert. PDE2 ist imstande, große Mengen 
von cAMP äußerst schnell zu hydrolisieren, so dass die Geschwindigkeit der 
cAMP-Hydrolyse viel höher ist als von cAMP-Synthese, was eine Grundlage 
der cAMP-Kompartimentierung sein könnte. cAMP-Sensoren wurden auch 
benutzt, um eine klinisch relevante diagnostische Methode zu entwickeln, die 
Autoantikörper gegen β1-adrenergen Rezeptoren bei Herzinsuffizienzpatienten 
zuverlässig nachweist. Diese Methode hat ermöglicht, die Sensitivität der früher 
entwickelten Techniken zu verbessern.  
Konformationsänderung in einzelnen Bindungsdomänen von GK und PDE 
wurde als nächstes benutzt, um ein Reihe neuer fluoreszierender Biosensoren für 
cGMP zu entwickeln. Diese Sensoren zeigten hohe räumliche und zeitliche 
Auslösung und wurden zur Analyse schneller Dynamik von cGMP-Synthese 
und für cGMP-Imaging in Mesangialzellen angewandt.  
Zusammenfassend wurden hochsensitive Biosensoren für cAMP und cGMP auf 
Grund einzelner, mit Grünfluoreszenzproteinmutanten fusionierter  Bindungs-
domäne entwickelt und in verschiedenen biologischen und klinisch relevanten 
Applikationen eingesetzt.     
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